[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2271
1. Derici H, Yaman I, Tansug T, Nazli O, Bozdag AD, Isguder AS: Prognostic Factors of Patients With Transmural Advanced Gastric Carcinoma. Gastroenterology Res; 2009 Dec;2(6):317-323

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic Factors of Patients With Transmural Advanced Gastric Carcinoma.
  • BACKGROUND: The purpose of this study is to evaluate perioperative morbidity, mortality and the prognostic factors that influence survival of the patients with transmural advanced gastric carcinoma after curative surgical therapy.
  • METHODS: Fifty patients with transmural advanced gastric adenocarcinoma underwent curative resection in our clinic.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27990200.001).
  • [ISSN] 1918-2805
  • [Journal-full-title] Gastroenterology research
  • [ISO-abbreviation] Gastroenterology Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Keywords] NOTNLM ; Advanced / Gastric Cancer / Morbidity / Mortality / Survival / Transmural
  •  go-up   go-down


2. Karim S, Ali A: Correlation of p53 over-expression and alteration in p53 gene detected by polymerase chain reaction-single strand conformation polymorphism in adenocarcinoma of gastric cancer patients from India. World J Gastroenterol; 2009 Mar 21;15(11):1381-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of p53 over-expression and alteration in p53 gene detected by polymerase chain reaction-single strand conformation polymorphism in adenocarcinoma of gastric cancer patients from India.
  • AIM: To study the alterations in p53 gene among Indian gastric cancer patients and to correlate them with the various clinicopathological parameters.
  • METHODS: A total of 103 gastric cancer patients were included in this study.
  • [MeSH-major] Adenocarcinoma / genetics. Exons / genetics. Gene Expression Regulation, Neoplastic. Genes, p53. Mutation. Polymerase Chain Reaction / methods. Stomach Neoplasms / genetics. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] DNA, Neoplasm / genetics. DNA, Neoplasm / isolation & purification. Gastric Mucosa / physiology. Gastric Mucosa / physiopathology. Gene Amplification. Humans. Immunohistochemistry. India. Polymorphism, Single-Stranded Conformational. Reference Values. Stomach / physiology. Stomach / physiopathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 1999 Oct;50(4):594-5; discussion 595-6 [10502192.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Am Surg. 2007 Apr;73(4):359-66 [17439029.001]
  • [Cites] J Gastroenterol. 2000;35 Suppl 12:111-5 [10779229.001]
  • [Cites] Indian J Gastroenterol. 2000 Apr-Jun;19(2):74-8 [10812820.001]
  • [Cites] Ann N Y Acad Sci. 2000 Jun;910:121-37; discussion 137-9 [10911910.001]
  • [Cites] East Afr Med J. 2000 Jan;77(1):27-30 [10944835.001]
  • [Cites] J Cancer Res Clin Oncol. 2001 Apr;127(4):207-16 [11315254.001]
  • [Cites] Int J Cancer. 2002 Jun 10;99(5):727-31 [12115507.001]
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] J Clin Pathol. 2004 Jun;57(6):585-90 [15166261.001]
  • [Cites] World J Gastroenterol. 2004 Aug 1;10(15):2174-8 [15259060.001]
  • [Cites] Pathobiology. 2004;71(4):201-10 [15263809.001]
  • [Cites] Cell. 1982 Feb;28(2):387-94 [6277513.001]
  • [Cites] Science. 1987 Oct 9;238(4824):193-7 [2889267.001]
  • [Cites] Genomics. 1989 Nov;5(4):874-9 [2687159.001]
  • [Cites] Nature. 1989 Dec 7;342(6250):705-8 [2531845.001]
  • [Cites] Cancer Res. 1991 Jun 1;51(11):3056-8 [2032245.001]
  • [Cites] Science. 1991 Jul 5;253(5015):49-53 [1905840.001]
  • [Cites] Cancer Res. 1991 Dec 1;51(23 Pt 1):6304-11 [1933891.001]
  • [Cites] Genes Chromosomes Cancer. 1992 Jan;4(1):1-15 [1377002.001]
  • [Cites] J Pathol. 1992 Apr;166(4):329-30 [1517889.001]
  • [Cites] PCR Methods Appl. 1991 Aug;1(1):34-8 [1842918.001]
  • [Cites] J Cancer Res Clin Oncol. 1993;119(5):265-72 [8440743.001]
  • [Cites] Gut. 1993 Mar;34(3):289-92 [8472973.001]
  • [Cites] Cancer Res. 1993 Jun 1;53(11):2614-7 [8495424.001]
  • [Cites] Genomics. 1993 May;16(2):325-32 [8314571.001]
  • [Cites] Am J Obstet Gynecol. 1993 Sep;169(3):690-4 [8372881.001]
  • [Cites] Hum Mutat. 1993;2(5):338-46 [8257985.001]
  • [Cites] J Pathol. 1993 Oct;171(2):151-2 [8283352.001]
  • [Cites] Cancer Genet Cytogenet. 1994 Jul 1;75(1):45-50 [8039163.001]
  • [Cites] Anticancer Res. 1994 May-Jun;14(3B):1251-5 [8067692.001]
  • [Cites] Cancer Res. 1994 Sep 15;54(18):4855-78 [8069852.001]
  • [Cites] Br J Cancer. 1994 Oct;70(4):585-90 [7917901.001]
  • [Cites] Blood. 1994 Oct 15;84(8):2391-411 [7919359.001]
  • [Cites] J Pathol. 1994 Jan;172(1):1-4 [7931821.001]
  • [Cites] J Pathol. 1994 Jan;172(1):5-12 [7931827.001]
  • [Cites] Oncogene. 1995 Feb 16;10(4):681-8 [7862445.001]
  • [Cites] Virchows Arch. 1995;426(5):447-55 [7633655.001]
  • [Cites] World J Surg. 1995 Sep-Oct;19(5):707-13 [7571667.001]
  • [Cites] Cancer. 1996 Apr 1;77(7):1244-9 [8608498.001]
  • [Cites] Semin Oncol. 1996 Jun;23(3):307-15 [8658214.001]
  • [Cites] J Gastroenterol Hepatol. 1996 Nov;11(11):1083-8 [8985835.001]
  • [Cites] Cancer. 1997 Jun 1;79(11):2067-72 [9179052.001]
  • [Cites] J Exp Clin Cancer Res. 1997 Jun;16(2):189-94 [9261746.001]
  • [Cites] Dig Dis Sci. 1997 Dec;42(12):2463-7 [9440620.001]
  • (PMID = 19294769.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ PMC2658834
  •  go-up   go-down


3. Duan L, Wu AH, Sullivan-Halley J, Bernstein L: Antacid drug use and risk of esophageal and gastric adenocarcinomas in Los Angeles County. Cancer Epidemiol Biomarkers Prev; 2009 Feb;18(2):526-33
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antacid drug use and risk of esophageal and gastric adenocarcinomas in Los Angeles County.
  • OBJECTIVES: Concern has been expressed that antacid drugs increase the risk of esophageal and gastric adenocarcinomas.
  • METHODS: This population-based case-control study recruited patients with incident esophageal adenocarcinoma (n = 220), gastric cardiac adenocarcinoma (n = 277), or distal gastric adenocarcinoma (n = 441) diagnosed between 1992 and 1997, and 1,356 control participants in Los Angeles County.
  • RESULTS: Among participants who took nonprescription acid neutralizing agents for >3 years, the odds ratio for esophageal adenocarcinoma was 6.32 compared with never users (95% confidence interval, 3.14-12.69; P(trend) < 0.01).
  • Analyses stratified by history of physician diagnosed upper gastrointestinal (UGI) disorders revealed a greater increase in esophageal adenocarcinoma risk associated with nonprescription antacid use among persons with no UGI disorder than among those with an UGI disorder (homogeneity of trends P = 0.07).
  • Regular use of nonprescription acid neutralizing agents was not associated with risk of adenocarcinomas of the gastric cardia or distal stomach.
  • CONCLUSION: We found risk of esophageal adenocarcinoma was greater among long-term nonprescription acid neutralizing drugs in participants without physician-diagnosed UGI conditions than among those with these conditions; this may represent self medication for undiagnosed precursor conditions or it may be that nonprescription acid neutralizing drugs, taken without limitation on amount used when symptoms are most intense, may permit alkaline bile reflux into the lower esophagus, thereby increasing esophageal adenocarcinoma risk.
  • [MeSH-major] Adenocarcinoma / chemically induced. Antacids / adverse effects. Esophageal Neoplasms / chemically induced. Stomach Neoplasms / chemically induced

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19190141.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / 5P30 ES07048; United States / NCI NIH HHS / CA / CA59636; United States / NCI NIH HHS / CN / N01 CN25403
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antacids
  •  go-up   go-down


Advertisement
4. Schneider S, Krikmann U, Lüüs SM, Kulla A, Haldre S: Neoplastic meningitis as the presenting manifestation of gastric adenocarcinoma. BMJ Case Rep; 2009;2009

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoplastic meningitis as the presenting manifestation of gastric adenocarcinoma.
  • The aetiology of the chronic meningitis was revealed gastric cancer by gastroscopy, and micrometastasis by bone marrow trephine biopsy.
  • Autopsy confirmed the presence of advanced gastric cancer (adenocarcinoma of signet-ring cell type) with pancreatic involvement, and NM with cancer cells on the meninges, but without infiltration tumour cells into underlying brain parenchyma.
  • We conclude that NM as an initial symptom of gastric cancer is rare and ultimately fatal.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Neurol. 2000 Dec;13(6):641-8 [11148663.001]
  • [Cites] Semin Oncol. 2006 Jun;33(3):312-23 [16769420.001]
  • [Cites] Curr Treat Options Oncol. 2001 Dec;2(6):517-27 [12057097.001]
  • [Cites] Curr Neurol Neurosci Rep. 2002 May;2(3):225-35 [11937001.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):167-74 [15015782.001]
  • [Cites] Lancet Neurol. 2006 May;5(5):443-52 [16632315.001]
  • (PMID = 21785656.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3029123
  •  go-up   go-down


5. van Lier MG, Bomhof FJ, Leendertse I, Flens M, Balk AT, Loffeld RJ: Cytokeratin phenotyping does not help in distinguishing oesophageal adenocarcinoma from cancer of the gastric cardia. J Clin Pathol; 2005 Jul;58(7):722-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokeratin phenotyping does not help in distinguishing oesophageal adenocarcinoma from cancer of the gastric cardia.
  • BACKGROUND: It is sometimes difficult to distinguish between cardia cancer and oesophageal cancer.
  • METHODS: Consecutive patients with a malignant tumour in the oesophagus or stomach were recruited.
  • RESULTS: Endoscopically located adenocarcinoma of the oesophagus was present in 84 patients (64 men, 20 women; mean age, 68 years; range, 44-91).
  • Cancer located primarily in the gastric cardia was present in 63 patients (42 men, 21 women; mean age, 68 years; range, 42-88).
  • The histological diagnosis was metastasis from a primary tumour outside the oesophagus or stomach in 19 patients.
  • Patients in group A had definite oesophageal cancer, group B patients had a definite carcinoma located in the gastric cardia, and group C patients had an obstructing tumour distal in the oesophagus at the level of the diaphragm, which could not be passed with the endoscope.
  • CONCLUSION: CK phenotyping cannot distinguish between cancer arising from a Barrett's oesophagus and carcinoma originating in the gastric cardia.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Cardia. Esophageal Neoplasms / diagnosis. Keratins / metabolism. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Adult. Aged. Aged, 80 and over. Barrett Esophagus / diagnosis. Barrett Esophagus / metabolism. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / metabolism. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Proteins / metabolism. Precancerous Conditions / diagnosis. Precancerous Conditions / metabolism

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 2001 Apr;38(4):307-11 [11318895.001]
  • [Cites] Hum Pathol. 1999 Mar;30(3):288-94 [10088547.001]
  • [Cites] Histol Histopathol. 2002 Apr;17(2):445-54 [11962749.001]
  • [Cites] Mod Pathol. 2002 Jun;15(6):611-6 [12065774.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1213-21 [12218578.001]
  • [Cites] Am J Gastroenterol. 2002 Oct;97(10):2514-23 [12385432.001]
  • [Cites] Neth J Med. 2003 Jan;61(1):14-8 [12688564.001]
  • [Cites] Histopathology. 2003 Aug;43(2):127-34 [12877727.001]
  • [Cites] Pathol Res Pract. 2003;199(9):581-7 [14621193.001]
  • [Cites] Histopathology. 2003 Nov;43(5):453-61 [14636271.001]
  • [Cites] Hum Pathol. 2004 Mar;35(3):371-6 [15017595.001]
  • [Cites] Gastroenterology. 1993 Feb;104(2):510-3 [8425693.001]
  • [Cites] Int J Cancer. 1993 May 28;54(3):402-7 [8509215.001]
  • [Cites] JAMA. 1993 Sep 15;270(11):1320 [8360967.001]
  • [Cites] Gastroenterol Clin North Am. 1997 Sep;26(3):487-94 [9309399.001]
  • [Cites] Lancet. 1997 Sep 27;350(9082):933 [9314878.001]
  • [Cites] Cancer. 2002 Feb 1;94(3):820-31 [11857318.001]
  • (PMID = 15976339.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 68238-35-7 / Keratins
  • [Other-IDs] NLM/ PMC1770716
  •  go-up   go-down


6. Nozawa K, Kaneko H, Itoh T, Katsura Y, Noguchi M, Suzuki F, Takasaki Y, Ogawa H, Takamori K, Sekigawa I: Synchronous malignant B-cell lymphoma and gastric tubular adenocarcinoma associated with paraneoplastic cutaneous vasculitis: hypereosinophilic syndrome with mixed cryoglobulinemia is an important sign of paraneoplastic syndrome. Rare Tumors; 2009;1(2):e42

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous malignant B-cell lymphoma and gastric tubular adenocarcinoma associated with paraneoplastic cutaneous vasculitis: hypereosinophilic syndrome with mixed cryoglobulinemia is an important sign of paraneoplastic syndrome.
  • Gastric adenocarcinoma developing concomitantly with a lymphoma is rare.
  • We report here a case with a synchronous diffuse large B-cell lymphoma (DLBCL) and an early adenocarcinoma of the stomach.
  • Our finding suggests that the potential presence of malignancies should be kept in mind as a possible underlying disorder especially in the presence of HES with MC; this possibility is interesting also as regards at least part of the pathogenesis for paraneplastic syndrome.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21139921.001).
  • [ISSN] 2036-3613
  • [Journal-full-title] Rare tumors
  • [ISO-abbreviation] Rare Tumors
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2994459
  • [Keywords] NOTNLM ; cryoglobulinemia / malignant lymphoma / paraneoplastic vasculitis / tubular adenocarcinoma.
  •  go-up   go-down


7. Duan L, Wu AH, Sullivan-Halley J, Bernstein L: Passive smoking and risk of oesophageal and gastric adenocarcinomas. Br J Cancer; 2009 May 5;100(9):1483-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Passive smoking and risk of oesophageal and gastric adenocarcinomas.
  • Few studies have examined the association between passive smoking and the risk of oesophageal and gastric adenocarcinomas.
  • In a population-based case-control study with 2474 participants in Los Angeles County, there was no evidence that passive smoking had any appreciable effect on oesophageal or gastric adenocarcinomas.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Secondhand Smoke.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Epidemiol. 1999 Oct;28(5):824-8 [10597977.001]
  • [Cites] Prev Med. 1984 Nov;13(6):680-90 [6536942.001]
  • [Cites] Am J Public Health. 1989 Feb;79(2):163-7 [2913834.001]
  • [Cites] Gut. 1998 Oct;43(4):537-41 [9824582.001]
  • [Cites] Int J Cancer. 1999 Jun 11;81(6):871-6 [10362132.001]
  • [Cites] Digestion. 1999 Sep-Oct;60(5):461-8 [10473971.001]
  • [Cites] Alcohol. 2005 Apr;35(3):259-64 [16054988.001]
  • [Cites] Am J Epidemiol. 2007 Jun 15;165(12):1424-33 [17420181.001]
  • [Cites] Cancer Causes Control. 2008 Sep;19(7):689-701 [18293090.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2000 Aug;12(8):837-42 [10958210.001]
  • [Cites] Cancer Causes Control. 2001 Oct;12(8):721-32 [11562112.001]
  • [Cites] Cancer Causes Control. 2001 Nov;12(9):797-802 [11714107.001]
  • [Cites] Eur J Cancer Prev. 2002 Feb;11(1):27-38 [11917206.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 2004;83:1-1438 [15285078.001]
  • [Cites] Free Radic Biol Med. 2000 Apr 1;28(7):1125-31 [10832074.001]
  • (PMID = 19352383.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / P30 ES007048; United States / NCI NIH HHS / CA / CA59636; United States / NCI NIH HHS / CN / N01CN25403; United States / NCI NIH HHS / CA / N01 CN025403; United States / NIEHS NIH HHS / ES / 5P30 ES07048
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Tobacco Smoke Pollution
  • [Other-IDs] NLM/ PMC2694436
  •  go-up   go-down


8. Richards DA, Boehm KA, Anthony SP: Systemic therapy for gastric cancer and adenocarcinoma of the gastroesophageal junction: present status and future directions. Expert Opin Investig Drugs; 2007 Jul;16(7):1059-68
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic therapy for gastric cancer and adenocarcinoma of the gastroesophageal junction: present status and future directions.
  • Gastric cancer is a major worldwide problem and is a leading cause of death.
  • The incidence of distal gastric cancer is declining; however, there has been a rapid rise in the incidence of adenocarcinoma of the gastroesophageal junction, which is a more aggressive entity.
  • This review examines recent advances in the treatment of gastroesophageal junction adenocarcinoma and gastric cancer, newer agents and the potential agents that are in development, which can be logically applied to the treatment of this devastating disease.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drugs, Investigational. Stomach Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17594189.001).
  • [ISSN] 1744-7658
  • [Journal-full-title] Expert opinion on investigational drugs
  • [ISO-abbreviation] Expert Opin Investig Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Drugs, Investigational
  • [Number-of-references] 56
  •  go-up   go-down


9. Mróz A, Kiedrowski M, Malinowska M, Sopyło R: Collision tumour of the stomach--adenocarcinoma and neuroendocrine carcinoma: case report and review of the literature. Pol J Pathol; 2009;60(2):94-7
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collision tumour of the stomach--adenocarcinoma and neuroendocrine carcinoma: case report and review of the literature.
  • We report a rare case of gastric collision tumour composed of poorly differentiated adenocarcinoma and neuroendocrine carcinoma in a 56-year-old Caucasian male.
  • The tumour was located in the gastric body and, to our knowledge, it is the tenth case described in the literature and the first in Poland.
  • The adenocarcinoma component constituted 20% of the lesion and was in a more advanced stage than the neuroendocrine component.
  • Additionally, the adenocarcinoma was the only one to metastasize to regional lymph nodes and the liver.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Neuroendocrine / pathology. Neoplasms, Multiple Primary / pathology. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Stomach carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19886184.001).
  • [ISSN] 1233-9687
  • [Journal-full-title] Polish journal of pathology : official journal of the Polish Society of Pathologists
  • [ISO-abbreviation] Pol J Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


10. Szkaradkiewicz A, Majewski W, Wal M, Czyzak M, Majewski P, Bierła J, Kuch A: Epstein-Barr virus (EBV) infection and p53 protein expression in gastric carcinoma. Virus Res; 2006 Jun;118(1-2):115-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus (EBV) infection and p53 protein expression in gastric carcinoma.
  • In the presented studies p53 protein expression was evaluated in samples of gastric carcinoma originating from 32 selected adult patients (with documented diagnosis of adenocarcinoma of the stomach and without the presence of Helicobacter pylori infection).
  • Among the patients 14 individuals carried EBV-positive gastric carcinoma (group 1) while the 18 remaining patients carried EBV-negative gastric carcinoma (group 2).
  • Presence of p53 protein was noted in 9 (64.3%) cases of EBV-positive gastric cancer (group 1) and in 10 (55.5%) cases of EBV-negative gastric cancer (group 2).
  • The results permit to conclude that abnormalities in p53 in gastric cancer are independent of EBV infection, even if EBV may participate in development of the tumour.
  • [MeSH-major] Adenocarcinoma / virology. Epstein-Barr Virus Infections / complications. Stomach Neoplasms / virology. Tumor Suppressor Protein p53 / biosynthesis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16413625.001).
  • [ISSN] 0168-1702
  • [Journal-full-title] Virus research
  • [ISO-abbreviation] Virus Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / Epstein-Barr virus encoded RNA 1; 0 / RNA, Viral; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


11. Lorenzen S, Hentrich M, Haberl C, Heinemann V, Schuster T, Seroneit T, Roethling N, Peschel C, Lordick F: Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial. Ann Oncol; 2007 Oct;18(10):1673-9
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial.
  • BACKGROUND: Phase II and III trials of docetaxel, cisplatin and fluorouracil (DCF) have shown superior efficacy versus cisplatin and fluorouracil alone but high rates of hematologic toxicity in advanced gastric cancer.
  • PATIENTS AND METHODS: Chemotherapy-naive patients with advanced gastric-/esophageal adenocarcinomas received T 50 mg/m(2) and P 50 mg/m(2) on days 1, 15 and 29 and L 500 mg/m(2) plus F 2000 mg/m(2) weekly, every 8 weeks.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17660494.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


12. Ott K, Lordick F: [Neoadjuvant therapy in the upper gastro-intestinal tract. Gastric cancer from a surgical viewpoint]. Chirurg; 2009 Nov;80(11):1028-34
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neoadjuvant therapy in the upper gastro-intestinal tract. Gastric cancer from a surgical viewpoint].
  • The prognosis of locally advanced gastric cancer remains poor.
  • Two randomized studies that have been performed in Europe have shown that peri-operative chemotherapy significantly improves the survival of patients with adenocarcinoma of the stomach and of the gastro-esophageal junction.
  • Neither mortality nor complication rate are increased after neoadjuvant chemotherapy for gastric cancer.
  • Patients with locally advanced gastric cancer should always be referred to experienced high volume centers, where the findings are discussed in a multidisciplinary tumor board.
  • [MeSH-major] Adenocarcinoma / surgery. Esophagogastric Junction. Neoadjuvant Therapy. Stomach Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3719-25 [17704421.001]
  • [Cites] N Engl J Med. 1999 Mar 25;340(12):908-14 [10089184.001]
  • [Cites] Int J Cancer. 2006 Dec 15;119(12):2885-94 [16929515.001]
  • [Cites] Lancet Oncol. 2006 Apr;7(4):309-15 [16574546.001]
  • [Cites] Clin Cancer Res. 2008 Apr 1;14 (7):2012-8 [18381939.001]
  • [Cites] Chirurg. 2006 Nov;77(11):971-80 [17066269.001]
  • [Cites] Chirurg. 2007 Sep;78(9):792-801 [17676284.001]
  • [Cites] Gastric Cancer. 2005;8(1):1-5 [15747167.001]
  • [Cites] Ann Surg Oncol. 2009 Apr;16(4):1017-25 [19189186.001]
  • [Cites] Ann Surg. 2007 Jul;246(1):1-8 [17592282.001]
  • [Cites] Chirurg. 2006 Mar;77(3):227-35 [16511688.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1521-30 [14508841.001]
  • [Cites] Radiology. 2006 May;239(2):472-80 [16543584.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5095-102 [17785563.001]
  • [Cites] Ann Surg. 1999 Mar;229(3):303-8 [10077040.001]
  • [Cites] Lancet Oncol. 2007 Sep;8(9):797-805 [17693134.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4692-8 [16966684.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):2307-15 [12796400.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2069-77 [15082726.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4604-10 [14673049.001]
  • [Cites] Ann Surg. 2004 Nov;240(5):808-16 [15492562.001]
  • [Cites] N Engl J Med. 2008 Jul 31;359(5):453-62 [18669424.001]
  • [Cites] Gastric Cancer. 2008;11(1):1-9 [18373171.001]
  • [Cites] Lancet Oncol. 2006 Aug;7(8):644-51 [16887481.001]
  • [Cites] N Engl J Med. 2007 Nov 1;357(18):1810-20 [17978289.001]
  • [Cites] J Am Coll Surg. 2007 Oct;205(4):593-601 [17903735.001]
  • [Cites] N Engl J Med. 2001 Sep 6;345(10):725-30 [11547741.001]
  • [Cites] Chirurg. 1999 May;70(5):520-9 [10412596.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):11-20 [16822992.001]
  • (PMID = 19756431.001).
  • [ISSN] 1433-0385
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 30
  •  go-up   go-down


13. Lee SH, Choi WC, Kim KS, Park JW, Lee SH, Yoon SW: Shrinkage of gastric cancer in an elderly patient who received Rhus verniciflua Stokes extract. J Altern Complement Med; 2010 Apr;16(4):497-500
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Shrinkage of gastric cancer in an elderly patient who received Rhus verniciflua Stokes extract.
  • PATIENT AND METHOD: We present here the case of a female patient (82 years old) with an adenocarcinoma of the stomach that was first diagnosed via an abdomen computed tomography (CT) scan and endoscopic biopsy.
  • CONCLUSIONS: We suggest that RVS extract could be a candidate for a natural agent that induces selective apoptosis and inhibits cell growth in gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Flavonoids / therapeutic use. Phytotherapy. Plant Extracts / therapeutic use. Rhus. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Aged, 80 and over. Female. Humans. Stomach / pathology

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20423218.001).
  • [ISSN] 1557-7708
  • [Journal-full-title] Journal of alternative and complementary medicine (New York, N.Y.)
  • [ISO-abbreviation] J Altern Complement Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Flavonoids; 0 / Plant Extracts
  •  go-up   go-down


14. Schuhmacher C, Schlag P, Lordick F, Hohenberger W, Heise J, Haag C, Gretschel S, Mauer ME, Lutz M, Siewert JR: Neoadjuvant chemotherapy versus surgery alone for locally advanced adenocarcinoma of the stomach and cardia: Randomized EORTC phase III trial #40954. J Clin Oncol; 2009 May 20;27(15_suppl):4510

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy versus surgery alone for locally advanced adenocarcinoma of the stomach and cardia: Randomized EORTC phase III trial #40954.
  • : 4510 Background: Combined pre- and postoperative chemotherapy improves overall survival in operable gastric cancer, although postoperative treatment is not feasible in half of the patients.
  • METHODS: Patients with locally advanced adenocarcinoma of the stomach and cardia were randomized between primary surgery or two 48-day cycles of weekly folinic acid 500 mg/m<sup>2</sup>/2h, 5-FU 2,000 mg/m<sup>2</sup>/24h plus biweekly cisplatin 50 mg/m<sup>2</sup>/1h followed by surgery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962708.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Nakayama N, Koizumi W, Sasaki T, Tanabe S, Nishimura K, Higuchi K, Takagi S, Katada C, Azuma M, Saigenji K: Phase II study of combination therapy with docetaxel, cisplatin, and S-1 (DCS) for advanced gastric cancer: (KDOG 0601). J Clin Oncol; 2009 May 20;27(15_suppl):4555

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of combination therapy with docetaxel, cisplatin, and S-1 (DCS) for advanced gastric cancer: (KDOG 0601).
  • : 4555 Background: Our previous phase I study (Oncology 2008, 75:1-7) provided evidence that combination chemotherapy with docetaxel, cisplatin, and S-1 (DCS) is effective and well tolerated in patients with advanced gastric cancer.
  • The present multicenter phase II study was conducted to confirm the efficacy and toxicity of DCS in advanced gastric cancer.
  • METHODS: Eligibility criteria included a histologically proved diagnosis of gastric adenocarcinoma with at least one measurable metastatic lesion, no previous treatment for gastric cancer except for surgery, an ECOG performance status of 0 to 2, and adequate organ function.
  • CONCLUSIONS: DCS was a well-tolerated regimen with a high response rate in patients with advanced gastric cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963030.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Lin R, Chen Q, Fan N, Ye Y, Guo Z, Wang X, Liu J, Chen L: Phase IIb trial of fluorouracil, leucovorin, oxaliplatin, and paclitaxel (POF) compared with fluorouracil, feucovorin, and irinotecan (IF) as first-line treatment for advanced gastric cancer (AGC). J Clin Oncol; 2009 May 20;27(15_suppl):e15642

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase IIb trial of fluorouracil, leucovorin, oxaliplatin, and paclitaxel (POF) compared with fluorouracil, feucovorin, and irinotecan (IF) as first-line treatment for advanced gastric cancer (AGC).
  • METHODS: Patients with previously untreated, advanced, unresectable, and histologically confirmed adenocarcinoma of the gastric or gastroesophageal junction were randomly assigned to POF or IF regiment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962736.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Cho S, Lee S, Hwang J, Bae W, Shim H, Park C, Park M, Chung I: Phase II study of S-1 monotherapy in taxane, cisplatin refractory gastric cancer. J Clin Oncol; 2009 May 20;27(15_suppl):4551

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of S-1 monotherapy in taxane, cisplatin refractory gastric cancer.
  • In previous study, S-1 demonstrated promising activity which is comparable to combination chemotherapy in advanced gastric cancer.
  • This phase II study evaluated the efficacy and safety of S-1 salvage chemotherapy, in patients with taxane and cisplatin refractory gastric cancer.
  • METHODS: Patients were eligible if they had histologically documented gastric adenocarcinoma previously treated with taxane (docetaxel or paclitaxel) and cisplatin; age≥18; Eastern Clinical Oncology Group (ECOG) performance status of 2 or less; adequate organ function; no evidence of gastrointestinal obstruction or passage disturbance.
  • CONCLUSIONS: This results showed that S-1 monotherapy was active and safe salvage chemotherapy in patients with advanced gastric cancer previously treated with taxane and cisplatin.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963034.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Thuss-Patience PC, Kretzschmar A, Deist T, Hinke A, Bichev D, Lebedinzew B, Schumacher G, Gebauer B, Maier V, Reichardt P: Irinotecan versus best supportive care (BSC) as second-line therapy in gastric cancer: A randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). J Clin Oncol; 2009 May 20;27(15_suppl):4540

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Irinotecan versus best supportive care (BSC) as second-line therapy in gastric cancer: A randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
  • : 4540 Background: Up to now the value of 2<sup>nd</sup>-line therapy for metastatic gastric cancer is unclear.
  • In this randomized phase III study we compared irinotecan to BSC to evaluate the value of 2<sup>nd</sup>- line chemotherapy for gastric cancer.
  • Eligibility: Metastatic or locally advanced gastro-esophageal junction or gastric adenocarcinoma.
  • CONCLUSIONS: To our knowledge this is the first randomized phase III study investigating 2<sup>nd</sup>- line chemotherapy in gastric cancer.
  • 2<sup>nd</sup>-line chemotherapy can now be considered as a proven option in gastric cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963017.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Shirao K, Boku N, Yamada Y, Yamaguchi K, Doi T, Takiuchi H, Nasu J, Nakamura K, Fukuda H, Ohtsu A: Randomized phase III study of 5-fluorouracil continuous infusion (5FUci) versus methotrexate and 5-FU sequential therapy (MF) in gastric cancer with peritoneal metastasis (JCOG0106). J Clin Oncol; 2009 May 20;27(15_suppl):4545

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase III study of 5-fluorouracil continuous infusion (5FUci) versus methotrexate and 5-FU sequential therapy (MF) in gastric cancer with peritoneal metastasis (JCOG0106).
  • : 4545 Background: Gastric cancer (GC) with peritoneal metastasis (PM) often complicates ascites or intestinal stenosis and the prognosis is still poor.
  • Anti-cancer drugs generally can not be administered for such patients (pts) due to the risk of serious and prolonged adverse events.
  • METHODS: Eligibility criteria included pts with histologically proven gastric adenocarcinoma; inoperable or recurrent GC; PM with radiologically confirmed intestinal stenosis or ascites; 20-75 years old; PS 0-2; no prior treatment except surgery or adjuvant chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963012.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Yoon J, Cho S, Bae W, Hwang J, Shim H, Chung I: Phase II study of irinotecan, 5-fluorouracil (5-FU) and leucovorin combination chemotherapy in taxane and cisplatin-based chemotherapy-refractory metastatic gastric cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15599

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of irinotecan, 5-fluorouracil (5-FU) and leucovorin combination chemotherapy in taxane and cisplatin-based chemotherapy-refractory metastatic gastric cancer.
  • : e15599 Background: The role of the second line chemotherapy in advanced gastric cancer was not clear, but possibility of prolongation of survival is open question.
  • Irinotecan is promising agents in gastric cancer and this phase II study evaluated the efficacy and safety of combination chemotherapy with irinotecan, high dose of 5-fluorouracil (5-FU) and leucovorin in taxane and cisplatin based chemotherapy refractory metastatic gastric cancer.
  • METHODS: Eligible criteria were as followed; histologic confirmed adenocarcinoma of stomach, previously treated with taxane and cisplatin, age≥18, Eastern Clinical Oncology Group (ECOG) performance status of 1 or less, adequate organ function.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962881.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Kakeji Y, Mizokami K, Sumiyoshi Y, Yoshinaga K, Saeki H, Tokunaga E, Endo K, Morita M, Kitao H, Emi Y, Maehara Y: The prognostic impact of hypoxia-inducible factor-1α and VEGF, IGF-2, p21, p53 expression in gastric adenocarcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):4571

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prognostic impact of hypoxia-inducible factor-1α and VEGF, IGF-2, p21, p53 expression in gastric adenocarcinoma.
  • The clinicopathological characteristics of human gastric cancer and the clinical outcomes were analyzed to investigate the effects of the expression of hypoxia-inducible factor1α (HIF-1α) and some related proteins, such as, vascular endothelial growth factor (VEGF), insulin-like growth factor-2 (IGF-2), p21, and p53 on the prognosis of human gastric cancer.
  • METHODS: The expressions of HIF-1α, VEGF, IGF-2, p21, and p53 proteins were determined by immunohistochemistry in 216 specimens of primary gastric cancer.
  • In addition, the HIF-1α expression positively correlated with the tumor size and depth of invasion, while it was also more frequent in tumors with lymphatic invasion and undifferentiated adenocarcinomas.
  • A multivariate Cox regression analysis showed the depth of invasion, lymph node metastasis, and HIF-1α positivity to all be independent prognostic factors in patients with gastric cancer.
  • CONCLUSIONS: Based on the above findings, HIF-1α is therefore considered to be a useful independent prognostic factor in gastric cancer, and the combination of a HIF-1α protein overexpression with the loss of p21 expression or nonfunctional p53 thus tends to indicate a dismal prognosis.
  • Controlling hypoxia, especially in the HIF-1α pathways, may therefore hold the key to a greater individualization of therapy and also lead to the development of new treatments for patients with gastric cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963078.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Younger people with gastric cancer have poor prognosis. Nurs Stand; 2009 Aug 05;23(48):14-17

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Younger people with gastric cancer have poor prognosis.
  • : Patients aged 35 and under who present with gastric adenocarcinoma are likely to have a more aggressive tumour type with both locally advanced and metastatic disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28038534.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


23. Aziz SA, Banday MA, Mir MH: Comparative efficacy of adjuvant chemoradiation versus chemotherapy in surgically resected adenocarcinoma of stomach. J Clin Oncol; 2009 May 20;27(15_suppl):e15639

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative efficacy of adjuvant chemoradiation versus chemotherapy in surgically resected adenocarcinoma of stomach.
  • : e15639 Background: Outcome of carcinoma of stomach has not changed over the past decades and surgery remains the time tested primary modality of treatment.
  • The present study focuses to compare the efficacy of adjuvant chemoradiation Vs Chemotherapy alone in surgically resected adenocarcinoma of stomach.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962750.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Kim S, Kim J, Chae Y, Sohn S, Moon J, Kang B, Chung H, Yu W, Baek J: Prognostic impact of the NFKB1 insertion/deletion promoter polymorphism on survival in patients with surgically resected gastric cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15638

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic impact of the NFKB1 insertion/deletion promoter polymorphism on survival in patients with surgically resected gastric cancer.
  • : e15638 Background: The present study analyzed the functional insertion/deletion polymorphism in the promoter region of NKFB1 gene and their impact on the prognosis for patients with gastric adenocarcinoma.
  • METHODS: Five hundred and three consecutive patients with surgically resected gastric adenocarcinoma were enrolled in the present study.
  • The multivariate survival analysis showed no association between the NFKB1 -94 insertion/deletion promoter polymorphism and the disease-free survival or overall survival of the patients with gastric cancer.
  • CONCLUSIONS: The functional NFKB1 promoter polymorphism was not found to be a prognostic marker for Korean patients with surgically resected gastric adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962749.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Lee J, Kang W, Lim D, Park J, Park Y, Lim H, Sohn T, Noh J, Bae J, Kim S: Phase III trial of adjuvant capecitabine/cisplatin (XP) versus capecitabine/cisplatin/RT (XPRT) in resected gastric cancer with D2 nodal dissection (ARTIST trial): Safety analysis. J Clin Oncol; 2009 May 20;27(15_suppl):4537

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase III trial of adjuvant capecitabine/cisplatin (XP) versus capecitabine/cisplatin/RT (XPRT) in resected gastric cancer with D2 nodal dissection (ARTIST trial): Safety analysis.
  • : 4537 Background: Although the adjuvant chemoradiation therapy has gained popularity and has become the standard of care in patients with resected gastric cancer in U.S., the role of chemoradiation therapy after extended D2 dissection has been questioned.
  • We conducted a phase III trial to compare capecitabine/cisplatin (XP) vs XP + radiotherapy (RT) in curatively D2 resected gastric cancer patients in terms of disease free survival and overall survival.
  • METHODS: Eligibility criteria were as follows: stage Ib (T1N1, T2bN0) - IV (M1 excluded), curatively ≥ D2 resected gastric adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962988.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Woell E, Greil R, Eisterer W, Fridrik M, Grünberger B, Zabernigg A, Mayrbäurl B, Russ G, Thaler J: Oxaliplatin, irinotecan, and cetuximab in advanced gastric cancer. First efficacy results of a multicenter phase II trial (AGMT Gastric-2) of the Arbeitsgemeinschaft Medikamentoese Tumortherapie (AGMT). J Clin Oncol; 2009 May 20;27(15_suppl):4538

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oxaliplatin, irinotecan, and cetuximab in advanced gastric cancer. First efficacy results of a multicenter phase II trial (AGMT Gastric-2) of the Arbeitsgemeinschaft Medikamentoese Tumortherapie (AGMT).
  • : 4538 Background: Patients (pts.) suffering from advanced gastric cancer have still a poor prognosis and treatment options are limited.
  • In our previous phase II trial (AGMT-Gastric-1) we could show that the combination of oxaliplatin and irinotecan was well tolerated and showed an objective response rate of 58% (Anticancer Res 28:2901-2906, 2008).
  • 51 patients with histological proven unresectable and/or metastatic gastric adenocarcinoma were treated in a first line setting.
  • CONCLUSIONS: The combination of oxaliplatin and irinotecan with cetuximab is feasible, safe and active in advanced gastric cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962987.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Servarayan CM, Chandramohan A, Datta D, Manickavasagam K: p53 and its influence in adenocarcinoma stomach. J Clin Oncol; 2009 May 20;27(15_suppl):e15685

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p53 and its influence in adenocarcinoma stomach.
  • : e15685 Background: Gastric cancer is the second most common cause of the malignancy in the world after lung cancer.
  • Various pathogenesis have been given for the adenocarcinoma, like mutation in the E-catherin gene, amplification of COX-2, HGF/ SF, VEGF; deletion of FHIT, APC, p53 but none have provided a definite target for treatment.
  • METHODS: This is a immunohistochemical prospective experiment study done on 76 cases of Gastric Adenocarcinoma.The location of the tumors were recorded as in the proximal stomach (fundus and body) and distal stomach (antrum, prepylorus, and pylorus).
  • 33 out of 60 (55%)of the males and 8 out of 16 (50%) females were reported of having gastric adenocarcinoma with p53expression.
  • The histology of the tissue samples from the gastric adenocarcinoma patients had following relationship with the p53 immunoreactivity, 20 out of 37 cases(54.05%) of the well differentiated,7 out of 17 cases (41.18% )of the moderately differentiated, and and 13 out of 21 cases(61.90%) of the poorly differentiated gastric adenocarcinoma showed positive immunoreactivity.
  • 15 out of 33 cases (45.45%)were localized to the proximal stomach and 30 out of 52 cases (57.69%)were localized to the distal stomach.
  • 52.63 % of the non-mucinous type of gastric adenocarcinoma showed positive p53 immunoreactivity.
  • The mutation is more marked in the poorly differentiated gastric adenocarcinoma.
  • The antral, pylorus,and the prepyloric parts of the stomach( the distal stomach) are more prone for mutated p53 induced adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962795.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Efremidis AP, Fostira F, Panopoulos C, Papademitriou K, Pistalmazian N, Tsoukalas N, Yannoukakos D: CDH-1 germ line mutations in diffuse gastric and infiltrating ductal breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e22218

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CDH-1 germ line mutations in diffuse gastric and infiltrating ductal breast cancer.
  • : e22218 Background: Hereditary Diffuse Gastric Cancer (HDGC) syndrome is characterized by the predisposition to gastric cancer of the diffuse type and to breast cancer of the lobular type.
  • The median age of onset for diffuse gastric cancer is 38 years.
  • CDH1 mutations are highly penetrant, conferring a cumulative risk of diffuse gastric cancer of 75%.
  • RESULTS: A pathogenic mutation located on exon 7 of the CDH1 gene was identified in a female patient diagnosed with bilateral breast cancer at the age of 36.
  • She underwent bilateral mastectomy for an infiltrating ductal adenocarcinoma of the left breast and in situ lobular of the right breast.
  • At the age of 45 the patient underwent gastrectomy for diffuse type gastric adenocarcinoma.
  • She had a positive family history for breast and gastric cancer from both sides, but without meeting the absolute clinical criteria for hereditary diffuse gastric cancer syndrome.
  • The nonsense mutation found was probably maternally inherited, since the maternal grandmother was diagnosed with breast cancer at the age of 38.
  • CONCLUSIONS: The selection process of patients for genetic testing for the HDGC syndrome is not quite clear at the moment, as it is apparent that more types of breast cancer and not only lobular, can be associated with the syndrome.
  • Criteria should be more flexible in respects to the histopathology of the cancer type.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964173.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Boukovinas I, Androulakis N, Polyzos A, Vardakis N, Amarantidis K, Bozionelou V, Kouroussis C, Giassas S, Christophyllakis C, Mavroudis D: A randomized phase II trial of irinotecan plus oxaliplatin versus oxaliplatin, fluorouracil (5 FU), leukovorin (LV) as first-line treatment in advanced gastric cancer. J Clin Oncol; 2009 May 20;27(15_suppl):4536

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized phase II trial of irinotecan plus oxaliplatin versus oxaliplatin, fluorouracil (5 FU), leukovorin (LV) as first-line treatment in advanced gastric cancer.
  • : 4536 Background: To compare the efficacy and tolerance of two oxaliplatin-based regimens as first-line treatment of advanced gastric cancer.
  • METHODS: Chemotherapy-naïve patients with measurable recurrent or metastatic gastric adenocarcinoma, PS (ECOG) 0-2 and adequate organ functions were randomly assigned to receive either irinotecan 200mg/m2 and oxaliplatin 80mg/m2 (IO), every 21 days or oxaliplatin 85mg/m<sup>2</sup> on day 1, 5-FU 400 mg/m<sup>2</sup> (over 1 hour infusion) + 600mg/m<sup>2</sup> (over 22 hours infusion) on days 1 and 2, leucovorin (LV) 200mg/m<sup>2</sup> on days 1 and 2 (FOLFOX4) every 2 weeks.
  • CONCLUSIONS: Both regimens are well tolerated and active in advanced gastric cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962990.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Oh S, Kim S, Kwon H, Kim H, Hwang I, Kang J, Lee S, Lee J, Kang W: Leptomeningeal carcinomatosis of gastric cancer: Multicenter retrospective analysis of 54 cases. J Clin Oncol; 2009 May 20;27(15_suppl):e15658

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leptomeningeal carcinomatosis of gastric cancer: Multicenter retrospective analysis of 54 cases.
  • : e15658 Background: Leptomeningeal carcinomatosis occurs in approximately 5% of patients with cancer.
  • The most common cancers involving the leptomeninges are breast and lung cancer.
  • However, gastric adenocarcinoma has been rarely reported with leptomeningeal carcinomatosis (LMC).
  • METHODS: We analyzed 54 cases of cytological confirmed gastric LMC at 4 institutions from 1994 to 2007.
  • The majority of patients had advanced disease at the initial diagnosis of gastric cancer.
  • The clinical or pathologic TNM stages of the primary gastric cancer were IV in 38 patients (70%).
  • The median interval from the diagnosis of the primary malignancy to the diagnosis of LMC was 6.3 months (range, 0 - 73.1 months).
  • Median OS duration from diagnosis of LMC was 6.7 weeks (95% CI; 4.3-9.1 weeks).
  • CONCLUSIONS: Although gastric LMC has dismal prognosis, IT and IV chemotherapy could be help to extend survival duration of gastric LMC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962774.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Glehen O, Elias D, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, Mansvelt B, Lorimier G, Association Française de Chirurgie: Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from digestive or primitive origin: A multi-institutional study of 1,290 patients. J Clin Oncol; 2009 May 20;27(15_suppl):4102

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The principal etiologies of PC were colorectal adenocarcinoma (N=523), pseudomyxoma peritonei (N=301), gastric adenocarcinoma (N=159), peritoneal mesothelioma (N=88), and appendiceal adenocarcinoma (N=50).
  • The overall median survival was 34 months: 30 months for colorectal PC, not reached for pseudomyxoma peritonei, 9 months for gastric PC, 41 months for peritoneal mesothelioma, and 77 months for PC from appendiceal adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961196.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Gallego R, Fuster D, Ginés A, Ortín J, Ayuso JR, Momblan D, Arguis P, Conill C, Pons F, Maurel J: Usefulness of PET/CT in the diagnosis of distant metastases of potentially operable gastric adenocarcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e15598

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of PET/CT in the diagnosis of distant metastases of potentially operable gastric adenocarcinoma.
  • 1) To evaluate the usefulness of Positron Emission Tomography with combined 18F-Fluorodeoxyglucose with Computed Tomography (PET/CT) in the diagnosis of distant metastases in patients with gastric adenocarcinoma (GAC) compared to spiral double contrast thoracoabdominal Computed Tomography (CT);.
  • METHODS: Thirty prospective patients (22 men, 8 women; mean age 67±11) who underwent endoscopic ultrasound and were classified as T2-3N1 or T3Nx GAC were included in this study.
  • In 1/3 patients with histopathological confirmed diagnosis of peritoneal carcinomatosis by laparoscopic findings was negative by PET/CT, and considered as a false negative case.
  • 1) PET/CT is useful in the diagnosis of distant metastases in patients with GAC 2) Further studies are needed to establish the role of PET/CT to detect peritoneal carcinomatosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962880.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Sym S, Park S, Park J, Kwon K, Jung I, Cho E, Lee W, Chung M, Shin D, Lee J: A randomized phase II trial of weekly docetaxel plus either cisplatin or oxaliplatin in patients with previously untreated advanced gastric cancer: Preliminary results. J Clin Oncol; 2009 May 20;27(15_suppl):4566

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized phase II trial of weekly docetaxel plus either cisplatin or oxaliplatin in patients with previously untreated advanced gastric cancer: Preliminary results.
  • METHODS: Chemotherapy-naïve patients with measurable unresectable and/or metastatic gastric adenocarcinoma and a performance status ≤2 were randomly assigned to receive docetaxel (35 mg/m2) weekly on days 1 and 8 of a 21-day cycle plus either cisplatin (60 mg/m2 on day 1) (arm A) or oxaliplatin (120 mg/m2 on day 1) (arm B).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963054.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Moon Y, Rha S, Jeung H, Shin S, Yoo N, Roh J, Noh S, Chung H: Clinical outcome of sequential chemotherapy in metastatic and/or recurrent gastric cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15521

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcome of sequential chemotherapy in metastatic and/or recurrent gastric cancer.
  • : e15521 Background: Little is known about data on subsequent chemotherapy (CTx) following 1<sup>st</sup>-line CTx in stage IV gastric cancer.
  • The purpose of this study was to analyze the natural history of stage IV gastric cancer with sequential CTx Methods: A total of 532 patients (pts) with unresectable gastric adenocarcinoma were studied.
  • Median overall survivals from diagnosis of unresectable cancer were 12.0/13.3/2.5 months for overall/CTx/BSC, respectively.
  • CONCLUSIONS: When pts with unresectable gastric cancer were managed with a strategy of maximal administration of CTx, a considerable number of pts could receive 2<sup>nd</sup> or 3<sup>rd</sup> line CTx, showing modest activity.
  • Our data on the natural history of stage IV gastric cancer with sequential CTx may suggest that clinical trials can be performed in a 2<sup>nd</sup> or 3<sup>rd</sup> line setting as well.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962260.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Kanzler S, Trarbach T, Seufferlein T, Kubicka S, Lordick F, Geissler M, Daum S, Galle PR, Moehler M, German Arbeitsgemeinschaft Internistische Onkologie (AIO): Cetuximab with irinotecan/folinic acid/5-FU as first-line treatment in advanced gastric cancer: A nonrandomized multicenter AIO phase II study. J Clin Oncol; 2009 May 20;27(15_suppl):4534

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cetuximab with irinotecan/folinic acid/5-FU as first-line treatment in advanced gastric cancer: A nonrandomized multicenter AIO phase II study.
  • : 4534 Background: Cetuximab has demonstrated high efficacy in combination with irinotecan-based therapies in metastatic colorectal cancer and irinotecan/folinic acid/5-FU (IF) may be an effective alternative to cisplatin-based regimens in advanced gastric cancer.
  • We therefore conducted a phase II AIO study to evaluate the tolerability and efficacy of cetuximab combined with IF as first-line treatment in patients with advanced gastric cancer.
  • METHODS: Patients (pts) were eligible with untreated adenocarcinoma of the stomach or oesophagogastric junction, with ECOG performance status (PS) < 2, measurable lesions and adequate organ functions.
  • RESULTS: Between Aug 2006 and Sep 2007, 49 pts were enrolled: 71% were males, median age was 63 years (range 33-77), median PS was 0 (65% pts), and 69% of pts and 31% of pts had gastric and oesophagogastric junction carcinomas, respectively.
  • Cetuximab combined with chemotherapy in advanced or metastatic gastric cancer is under further investigation in an ongoing phase III trial.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962992.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Jhawer M, Kindler HL, Wainberg Z, Ford J, Kunz P, Tang L, McCallum S, Kallender H, Shah MA, MET111643 Investigators and GlaxoSmithKline: Assessment of two dosing schedules of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric cancer (GC): Interim results of a multicenter phase II study. J Clin Oncol; 2009 May 20;27(15_suppl):4502

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of two dosing schedules of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric cancer (GC): Interim results of a multicenter phase II study.
  • METHODS: Pts with distal esophagus, GE junction or stomach adenocarcinoma, 0-2 prior chemotherapy regimens, adequate organ function, measurable disease, and ECOG PS 0-2 are sequentially enrolled in 2 cohorts:.
  • Single agent GSK089 demonstrates minimal antitumor activity in a cMET-unselected gastric population on the 5 on/9 off schedule.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962690.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Lu M, Shen L: Recurrence patterns of Chinese patients with gastric cancer after complete resection. J Clin Oncol; 2009 May 20;27(15_suppl):e15667

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence patterns of Chinese patients with gastric cancer after complete resection.
  • : e15667 Background: Recurrence after radical resection was the most important factor that influence the prognosis of patients with gastric adenocarcinoma.
  • Focusing on the clinicopathologic features and recurrence patterns, this study aims to find the characteristics of recurrence pattern and the predictive factors of gastric cancer patients in China.
  • METHODS: This is a retrospective analysis of the gastric adenocarcinoma patients who accepted adjuvant treatment and follow up in our medical department after R0 resection.
  • Locoregional recurrence was defined as dominant masses in the gastric bed, regional nodes or anastomotic recurrence.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962752.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Mohri Y, Kageyama S, Mohri T, Tanaka K, Ohi M, Yokoe T, Kusunoki M: Macrophage migration inhibitory factor and long-term survival in gastric cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15525

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Macrophage migration inhibitory factor and long-term survival in gastric cancer.
  • : e15525 Background: Our study aimed to evaluate whether pretherapeutic serum macrophage migration inhibitory factor (MIF) is an independent factor predicting long-term survival in gastric cancer.
  • Gastric cancer is the second leading cause of cancer-related deaths worldwide, but no satisfactory tumor marker exists.
  • We recently found serum MIF expression was progressively increased in gastric cancer.
  • METHODS: One hundred five patients, 73 men and 32 women, mean (±SD) age 63±14 years, with histologically proven gastric adenocarcinoma were included in the study.
  • CONCLUSIONS: The serum level of MIF is a potentially valuable pretherapeutic prognostic factor in patients with gastric cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962256.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. El-Rayes BF, Patel B, Zalupski M, Hammad N, Shields A, Heilbrun L, Venkatramanamoorthy R, Philip P: A phase II study of bevacizumab, docetaxel, and oxaliplatin in gastric and GEJ cancer. J Clin Oncol; 2009 May 20;27(15_suppl):4563

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of bevacizumab, docetaxel, and oxaliplatin in gastric and GEJ cancer.
  • : 4563 Background: VEGF (vascular endothelial growth factor) has a central role in angiogenesis, tumor growth and metastasis of gastric cancer.
  • METHODS: The primary endpoint was time to progression (TTP) in patients with locally advanced or metastatic adenocarcinoma of the gastric or gastroesophageal junction treated with docetaxel, oxaliplatin and bevacizumab.
  • RESULTS: A total of 23 patients (median age 57, males 70%, gastric 52%) were enrolled on the study.
  • At this time, bevacizumab should not be used in gastric or gastroesophageal junction cancers outside of a clinical trial until its safety is well established.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963057.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Chadha MK, Fakih MG, Tian L, Mashtare T, Nesline M, Davis W, Silliman C, Trump DL: Effect of 25 hydroxy vitamin D status on serological response to influenza vaccine in cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):e20575

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of 25 hydroxy vitamin D status on serological response to influenza vaccine in cancer patients.
  • We conducted a prospective influenza vaccination study to determine the influence of vitamin D status on serological response to flu vaccine in cancer patients.
  • METHODS: Cancer patients at Roswell Park Cancer Institute were offered trivalent (H1N1, H3N2, B/Malaysia) Flu vaccine (Fluzone, 2006-7) and sera collected for hemagglutination inhibition (HI) assay titers.
  • Logistic regression model was used using other covariates such as age, gender, cancer type, and chemotherapy (CT) as controls.
  • RESULTS: 85 patients with colorectal, 35 with prostate, 1 with anal and 1 with gastric adenocarcinoma participated in the study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961109.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Uchiyama Y, Murakami S, Kakimoto N, Nakatani A, Kishino M, Hamab Y, Furukawa S: Diagnostic imaging findings for mandibular metastasis from gastric adenocarcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2009 Jun;107(6):e49-53
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic imaging findings for mandibular metastasis from gastric adenocarcinoma.
  • A case of metastatic adenocarcinoma from gastric cancer to the mandibular canine region is reported.
  • [MeSH-major] Adenocarcinoma / secondary. Gingival Neoplasms / secondary. Mandibular Neoplasms / secondary. Osteolysis / radiography. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19464643.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Siew LC, Huang C, Fleming J: Gastric adenocarcinoma mistakenly diagnosed as an eating disorder: case report. Int J Eat Disord; 2010 Apr;43(3):286-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric adenocarcinoma mistakenly diagnosed as an eating disorder: case report.
  • OBJECTIVE: A number of organic conditions may mimic the symptoms of an eating disorder, however, gastric outlet obstruction mimicking anorexia nervosa has rarely been reported.
  • METHOD: We report the case of a 51-year-old female admitted to an eating disorders unit with an initial diagnosis of anorexia nervosa.
  • RESULTS: The patient's upper gastrointestinal symptoms and weight loss were found to be secondary to gastric outlet obstruction from a gastric adenocarcinoma.
  • Coincidental psychosocial stressors and past psychiatric history, among other factors, had confounded the diagnosis.
  • DISCUSSION: Organic causes of weight loss and upper gastrointestinal symptoms need to be fully excluded prior to making the diagnosis of an eating disorder, particularly when there are atypical features in the presentation.
  • [MeSH-major] Adenocarcinoma / diagnosis. Anorexia Nervosa / diagnosis. Diagnostic Errors. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Body Mass Index. Depressive Disorder, Major / diagnosis. Depressive Disorder, Major / psychology. Dyspepsia / etiology. Energy Intake. Female. Gastric Outlet Obstruction / diagnosis. Gastric Outlet Obstruction / psychology. Gastroscopy. Humans. Middle Aged. Thinness / diagnosis. Thinness / psychology. Tomography, X-Ray Computed. Vomiting / etiology. Weight Loss

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19365820.001).
  • [ISSN] 1098-108X
  • [Journal-full-title] The International journal of eating disorders
  • [ISO-abbreviation] Int J Eat Disord
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Richards D, McCollum D, Wilfong L, Sborov M, Boehm KA, Zhan F, Asmar L: Phase II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer and/or adenocarcinoma of the gastroesophageal junction. Ann Oncol; 2008 Jan;19(1):104-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer and/or adenocarcinoma of the gastroesophageal junction.
  • BACKGROUND: Platinum-based chemotherapy is the standard treatment for advanced gastric cancer (GC).
  • PATIENTS AND METHODS: Patients with untreated stage IV GC or adenocarcinoma of the gastroesophageal junction (AGEJ) received docetaxel 60 mg/m(2) followed by oxaliplatin 130 mg/m(2) on day 1 of each 21-day cycle until progression or unacceptable toxicity.
  • RESULTS: Baseline characteristics (N = 71): median age 59 years, 72% male, 51% esophagogastric junction cancer, and Eastern Cooperative Oncology Group performance status of zero, one, two were 42%, 51%, 7%, respectively.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CALCIUM GLUCONATE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. MAGNESIUM SULFATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17897959.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 0 / Taxoids; 04ZR38536J / oxaliplatin; 15H5577CQD / docetaxel; 7487-88-9 / Magnesium Sulfate; 7S5I7G3JQL / Dexamethasone; SQE6VB453K / Calcium Gluconate
  •  go-up   go-down


44. Kaira K, Sunaga N, Yanagitani N, Hisada T, Ishizuka T, Mori M: Pseudomesotheliomatous adenocarcinoma of the lung with synchronous gastric and esophageal cancer. Australas Radiol; 2007 Dec;51 Suppl:B265-7
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudomesotheliomatous adenocarcinoma of the lung with synchronous gastric and esophageal cancer.
  • Pseudomesotheliomatous adenocarcinoma is an uncommon variant of peripheral lung cancer.
  • An immunohistochemical investigation is important when it is difficult to determine whether diffuse carcinomatous involvement of the pleura is secondary to metastasis, lung cancer, or mesothelioma.
  • We herein report a very rare case of concomitant pseudomesotheliomatous adenocarcinoma, gastric cancer and esophageal cancer.
  • [MeSH-major] Adenocarcinoma / diagnosis. Diagnostic Imaging / methods. Esophageal Neoplasms / diagnosis. Lung Neoplasms / diagnosis. Mesothelioma / diagnosis. Neoplasms, Second Primary / diagnosis. Stomach Neoplasms / diagnosis


45. Yu HP, Yu XH, Zhang SX: [Expression and significance of macrophage migration inhibitory factor in gastric adenocarcinoma]. Zhonghua Yi Xue Za Zhi; 2010 Oct 12;90(37):2625-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and significance of macrophage migration inhibitory factor in gastric adenocarcinoma].
  • OBJECTIVE: To investigate the expression of MIF on the gastric adenocarcinoma, evaluate the relation between the MIF expression and tumor differentiation, lymph node metastasis and other clinical patho-features.
  • METHODS: 120 gastric adenocarcinoma cancer tissues, 40 tissues besides cancer and 40 common mucosa tissues specimens are collected.
  • RESULTS: Positive rate of MIF expression in gastric cancer is 80.8% (97/120).
  • Those in poorly differentiated, moderately differentiated and well-differentiated gastric adenocarcinoma are 97.5% (39/40), 82.5% (33/40), 62.5% (25/40), analytical factor of Spearman rank correlation r(s) is 0.458 (χ(2) = 27.046, P < 0.001).
  • Positive rate of MIF expression in tissues besides cancer is 40% (16/40) and that in normal gastric mucosa is 7.5% (3/40).
  • Positive rate of MIF expression in gastric adenocarcinoma without lymph node metastasis is 40% (22/55) and the rate with lymph node metastasis is 67% (44/65).
  • CONCLUSIONS: There is overexpression of MIF in the gastric adenocarcinoma.
  • Expression of MIF in different differentiated cancer is different.
  • Expression in poorly differentiated is higher than that in moderately differentiated and well-differentiated cancer.
  • The level of expression of MIF malignancy has positive correlation with malignancy degree of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Intramolecular Oxidoreductases / metabolism. Macrophage Migration-Inhibitory Factors / metabolism. Stomach Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Female. Gastric Mucosa / metabolism. Gastric Mucosa / pathology. Humans. Lymphatic Metastasis. Male. Middle Aged. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21162929.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Macrophage Migration-Inhibitory Factors; EC 5.3.- / Intramolecular Oxidoreductases; EC 5.3.2.1 / MIF protein, human
  •  go-up   go-down


46. Chandanos E, Lindblad M, Rubio CA, Jia C, Warner M, Gustafsson JA, Lagergren J: Tamoxifen exposure in relation to gastric adenocarcinoma development. Eur J Cancer; 2008 May;44(7):1007-14
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tamoxifen exposure in relation to gastric adenocarcinoma development.
  • Epidemiological research has indicated that the anti-oestrogen tamoxifen, used in breast cancer therapy, may increase the risk of gastric adenocarcinoma of the intestinal but not of the diffuse type.
  • The study participants comprised women in the county of Stockholm who in the Swedish Cancer Register were first recorded with breast cancer and subsequently gastric cancer during the period January 1958-August 2005.
  • Tumour material was reviewed histologically to verify gastric adenocarcinoma diagnosis and classify these cancers into intestinal or diffuse type.
  • Intestinal adenocarcinomas were analysed immunohistochemically for the presence of ER alpha, beta and beta cx.
  • Amongst 68 women with verified gastric adenocarcinoma, 30 had been treated with tamoxifen and 38 not.
  • The intestinal type of gastric adenocarcinoma was not more frequent amongst tamoxifen users (27%) than amongst non-users (34%) (p=0.601).
  • There were no material differences between the tamoxifen groups regarding distribution of any of the three ERs of the intestinal adenocarcinoma specimens.
  • Tamoxifen users had a shorter latency between breast cancer and gastric adenocarcinoma (4 versus 13 years) which was similar in the intestinal and diffuse types.
  • This study does not support the hypothesis that tamoxifen increases the isolated risk of the intestinal type, but it indicates that tamoxifen use might accelerate the tumour progression or increase the overall risk of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / chemically induced. Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Stomach Neoplasms / chemically induced. Tamoxifen / adverse effects
  • [MeSH-minor] Adult. Age of Onset. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Cohort Studies. Disease Progression. Female. Gastric Mucosa / metabolism. Humans. Middle Aged. Receptors, Estrogen / metabolism. Risk Factors. Stomach / metabolism. Sweden

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18394879.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


47. Chekrine T, Tawfiq N, Bouchbika Z, Benchakroun N, Jouhadi H, Sahraoui S, Benider A: [Ocular metastasis heralding gastric adenocarcinoma]. Rev Med Interne; 2010 Oct;31(10):e14-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ocular metastasis heralding gastric adenocarcinoma].
  • [Transliterated title] Métastase oculaire inaugurale d'un adénocarcinome gastrique.
  • Ocular metastasis is a rare presenting feature of gastric adenocarcinoma.
  • Diagnostic work-up identified a gastric adenocarcinoma with pulmonary metastases.
  • The patient died 6 months after the diagnosis of respiratory failure.

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Société nationale française de médecine interne (SNFMI). Published by Elsevier SAS. All rights reserved.
  • (PMID = 20554090.001).
  • [ISSN] 1768-3122
  • [Journal-full-title] La Revue de medecine interne
  • [ISO-abbreviation] Rev Med Interne
  • [Language] FRE
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


48. Wideroff L, Vaughan TL, Farin FM, Gammon MD, Risch H, Stanford JL, Chow WH: GST, NAT1, CYP1A1 polymorphisms and risk of esophageal and gastric adenocarcinomas. Cancer Detect Prev; 2007;31(3):233-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] GST, NAT1, CYP1A1 polymorphisms and risk of esophageal and gastric adenocarcinomas.
  • BACKGROUND: Polymorphisms in glutathione-S-transferase (GST), N-acetyltransferase (NAT) 1, and CYP1A1 genes have been suggested as susceptibility factors for esophageal and gastric adenocarcinomas, but have not been consistently linked to elevated risks.
  • Population controls from the same catchment areas were frequency matched to expected age and sex distributions of esophageal and gastric cardia adenocarcinomas.
  • DNA was extracted from buffy coat for PCR-based assays, with interpretable genotyping results obtained from 209 controls, 67 esophageal adenocarcinomas, 60 gastric cardia adenocarcinomas, and 56 noncardia gastric adenocarcinomas.
  • The respective ORs for esophageal, cardia, and other gastric adenocarcinomas were 1.73 (0.75-4.02), 1.46 (0.57-3.73), and 1.22 (0.48-3.09).
  • CONCLUSIONS: Additional research in larger samples is needed to further assess polymorphisms and their interactions with epidemiologic risk factors, particularly for esophageal adenocarcinoma, which has been increasing markedly in incidence.
  • [MeSH-major] Adenocarcinoma / genetics. Arylamine N-Acetyltransferase / genetics. Cytochrome P-450 CYP1A1 / genetics. Esophageal Neoplasms / genetics. Glutathione Transferase / genetics. Isoenzymes / genetics. Polymorphism, Genetic. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gastroenterol. 2004;39(3):220-30 [15064998.001]
  • [Cites] DNA Cell Biol. 1990 Apr;9(3):193-203 [2340091.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Nov;87(22):8923-7 [2247466.001]
  • [Cites] Cancer Causes Control. 1993 Mar;4(2):123-32 [8481491.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1995 Mar;4(2):85-92 [7742727.001]
  • [Cites] PCR Methods Appl. 1995 Jun;4(6):357-62 [7580930.001]
  • [Cites] Cancer Res. 1995 Nov 15;55(22):5226-9 [7585580.001]
  • [Cites] Pharmacogenetics. 1996 Apr;6(2):187-91 [9156696.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 3;89(17):1277-84 [9293918.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Nov;7(11):1013-8 [9829710.001]
  • [Cites] Cancer Res. 1999 Feb 1;59(3):586-9 [9973204.001]
  • [Cites] World J Gastroenterol. 2004 Dec 1;10(23):3389-93 [15526353.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Jan;9(1):3-28 [10667460.001]
  • [Cites] Pharmacogenetics. 2001 Nov;11(8):655-61 [11692073.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Dec;10(12):1239-48 [11751440.001]
  • [Cites] Int J Epidemiol. 2001 Dec;30(6):1415-25 [11821356.001]
  • [Cites] World J Gastroenterol. 2002 Feb;8(1):49-53 [11833070.001]
  • [Cites] J Gastrointest Surg. 2002 May-Jun;6(3):359-67 [12022988.001]
  • [Cites] Int J Cancer. 2002 Jul 20;100(3):249-60 [12115538.001]
  • [Cites] Cancer Lett. 2002 Dec 15;188(1-2):95-102 [12406553.001]
  • [Cites] Cancer. 2002 Nov 15;95(10):2096-102 [12412162.001]
  • [Cites] Surg Oncol Clin N Am. 2002 Apr;11(2):235-56 [12424848.001]
  • [Cites] Neurosci Lett. 2003 Jan 30;337(1):5-8 [12524158.001]
  • [Cites] Cancer Detect Prev. 2003;27(2):139-46 [12670526.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Apr;12(4):384-6 [12692115.001]
  • (PMID = 17646057.001).
  • [ISSN] 0361-090X
  • [Journal-full-title] Cancer detection and prevention
  • [ISO-abbreviation] Cancer Detect. Prev.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01 CA057949-03; United States / NCI NIH HHS / CA / U01 CA057923-03; United States / NCI NIH HHS / CA / U01 CA057983-03; United States / NIEHS NIH HHS / ES / P30 ES010126; United States / NCI NIH HHS / CA / U01 CA057949; United States / NCI NIH HHS / CA / U01 CA057983; United States / Intramural NIH HHS / / Z99 DA999999; United States / NCI NIH HHS / CA / U01 CA057923; United States / NIEHS NIH HHS / ES / P30 ES007033; United States / NCI NIH HHS / CP / N01 CP040501; United States / NIEHS NIH HHS / ES / P30 ES010126-07; United States / NCI NIH HHS / CP / N01 CP040501-09; United States / NCI NIH HHS / CP / N01CP040501-009; United States / NCI NIH HHS / CN / N01 CN005230; United States / NIEHS NIH HHS / ES / P30 ES007033-13
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Isoenzymes; EC 1.14.14.1 / Cytochrome P-450 CYP1A1; EC 2.3.1.5 / Arylamine N-Acetyltransferase; EC 2.3.1.5 / N-acetyltransferase 1; EC 2.5.1.- / glutathione S-transferase T1; EC 2.5.1.18 / GSTP1 protein, human; EC 2.5.1.18 / Glutathione S-Transferase pi; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase M1
  • [Other-IDs] NLM/ NIHMS29977; NLM/ PMC2268246
  •  go-up   go-down


49. Riles WL, Erickson J, Nayyar S, Atten MJ, Attar BM, Holian O: Resveratrol engages selective apoptotic signals in gastric adenocarcinoma cells. World J Gastroenterol; 2006 Sep 21;12(35):5628-34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resveratrol engages selective apoptotic signals in gastric adenocarcinoma cells.
  • AIM: To investigate the intracellular apoptotic signals engaged by resveratrol in three gastric adenocarcinoma cancer cell lines, two of which (AGS and SNU-1) express p53 and one (KATO-III) with deleted p53.
  • RESULTS: Gastric cancer cells, irrespective of their p53 status, responded to resveratrol with fragmentation of DNA and cleavage of nuclear lamins A and B and PARP.
  • Resveratrol, however, has no effect on mitochondria-associated apoptotic proteins Bcl-2, Bcl-xl, Bax, Bid or Smac/Diablo, and did not promote sub-cellular redistribution of cytochrome C, indicating that resveratrol-induced apoptosis of gastric carcinoma cells does not require breakdown of mitochondrial membrane integrity.
  • CONCLUSION: These findings indicate that even within a specific cancer the intracellular apoptotic signals engaged by resveratrol are cell type dependent and suggest that such differences may be related to differentiation or lack of differentiation of these cells.
  • [MeSH-major] Adenocarcinoma / pathology. Antineoplastic Agents, Phytogenic / pharmacology. Apoptosis / drug effects. Stilbenes / pharmacology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. RESVERATROL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatology. 2000 Apr;31(4):922-31 [10733549.001]
  • [Cites] Cell Biol Int. 2001;25(4):331-8 [11319839.001]
  • [Cites] Carcinogenesis. 2001 Oct;22(10):1633-9 [11577002.001]
  • [Cites] J Clin Invest. 2001 Oct;108(7):991-9 [11581300.001]
  • [Cites] Biochem Pharmacol. 2001 Nov 15;62(10):1423-32 [11709203.001]
  • [Cites] Int J Cancer. 2001 Dec 1;94(5):615-22 [11745454.001]
  • [Cites] N Engl J Med. 2002 Jan 3;346(1):65-7 [11778008.001]
  • [Cites] J Biol Chem. 2002 Feb 1;277(5):3247-57 [11714700.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2002 May;282(5):G809-16 [11960777.001]
  • [Cites] Ann N Y Acad Sci. 2002 May;957:210-29 [12074974.001]
  • [Cites] Br J Cancer. 2002 Jul 1;87(1):91-7 [12085263.001]
  • [Cites] Cancer Lett. 2003 Feb 20;190(2):157-63 [12565170.001]
  • [Cites] BMC Cancer. 2002 Oct 17;2:27 [12383351.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7724-32 [14633697.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Dec 26;312(4):1178-84 [14651997.001]
  • [Cites] Cancer Res. 2004 Jan 1;64(1):337-46 [14729643.001]
  • [Cites] Mol Cancer Ther. 2004 Jan;3(1):71-84 [14749477.001]
  • [Cites] J Altern Complement Med. 2004 Apr;10(2):235-9 [15165403.001]
  • [Cites] Gastroenterol Jpn. 1987 Aug;22(4):419-27 [2444485.001]
  • [Cites] Science. 1997 Jan 10;275(5297):218-20 [8985016.001]
  • [Cites] Science. 1997 Mar 14;275(5306):1649-52 [9054359.001]
  • [Cites] Cancer Res. 1998 May 1;58(9):1808-12 [9581817.001]
  • [Cites] Cancer. 1998 Aug 1;83(3):435-44 [9690535.001]
  • [Cites] Carcinogenesis. 1999 Feb;20(2):237-42 [10069459.001]
  • [Cites] Biochem Pharmacol. 1998 May 1;55(9):1339-46 [10076523.001]
  • [Cites] Drugs Exp Clin Res. 1999;25(2-3):87-97 [10370869.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] World J Gastroenterol. 2005 Jan 14;11(2):280-4 [15633232.001]
  • [Cites] Invest New Drugs. 2005 Mar;23(2):111-9 [15744586.001]
  • [Cites] Cell Death Differ. 2000 Sep;7(9):834-42 [11042678.001]
  • (PMID = 17007014.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / BIRC5 protein, human; 0 / Fas-Associated Death Domain Protein; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Stilbenes; 0 / Tumor Suppressor Protein p53; EC 1.9.3.1 / Electron Transport Complex IV; EC 3.4.22.- / Caspases; Q369O8926L / resveratrol
  • [Other-IDs] NLM/ PMC4088162
  •  go-up   go-down


50. Shibata T, Mahotka C, Wethkamp N, Heikaus S, Gabbert HE, Ramp U: Disturbed expression of the apoptosis regulators XIAP, XAF1, and Smac/DIABLO in gastric adenocarcinomas. Diagn Mol Pathol; 2007 Mar;16(1):1-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disturbed expression of the apoptosis regulators XIAP, XAF1, and Smac/DIABLO in gastric adenocarcinomas.
  • To explore the relevance of XIAP, Smac/DIABLO, and XAF1 for carcinogenesis and tumor progression, we analyzed 46 primary gastric adenocarcinomas and non-neoplastic gastric mucosa samples by quantitative real-time polymerase chain reaction.
  • XIAP, Smac/DIABLO, and XAF1 expression was found in all non-neoplastic gastric mucosa samples and all adenocarcinomas.
  • XIAP expression levels did not change between non-neoplastic gastric mucosa and adenocarcinomas or between carcinomas of early and advanced stages.
  • XAF1 expression had the tendency to decrease from non-neoplastic mucosa to advanced adenocarcinomas.
  • Importantly, the ratio of XIAP to XAF1 expression significantly (P=0.03) increased from non-neoplastic mucosa to adenocarcinomas and the increase was even higher in carcinomas of advanced stage (P=0.01).
  • In conclusion, an increased expression ratio of XIAP to XAF1 in combination with a disturbed expression of the XAF1 splice variants could be shown in gastric adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / metabolism. Apoptosis. Apoptosis Regulatory Proteins / metabolism. Stomach Neoplasms / metabolism
  • [MeSH-minor] Alternative Splicing. Gastric Mucosa / metabolism. Humans. Intracellular Signaling Peptides and Proteins / genetics. Intracellular Signaling Peptides and Proteins / metabolism. Mitochondrial Proteins / genetics. Mitochondrial Proteins / metabolism. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism. RNA, Messenger / analysis. RNA, Messenger / metabolism. Up-Regulation. X-Linked Inhibitor of Apoptosis Protein / genetics. X-Linked Inhibitor of Apoptosis Protein / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17471152.001).
  • [ISSN] 1052-9551
  • [Journal-full-title] Diagnostic molecular pathology : the American journal of surgical pathology, part B
  • [ISO-abbreviation] Diagn. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / DIABLO protein, human; 0 / Intracellular Signaling Peptides and Proteins; 0 / Mitochondrial Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / X-Linked Inhibitor of Apoptosis Protein; 0 / XAF1 protein, human; 0 / XIAP protein, human
  •  go-up   go-down


51. Tormo Ferrero V, Andreu Martínez FJ, Cardenal Macía R, Pomares Arias A: Evaluation of the toxicity of the combined treatment of chemoradiotherapy, according to the scheme of Macdonald, after radical surgery in patients diagnosed of gastric cancer. Clin Transl Oncol; 2006 Aug;8(8):611-5
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the toxicity of the combined treatment of chemoradiotherapy, according to the scheme of Macdonald, after radical surgery in patients diagnosed of gastric cancer.
  • PURPOSE: In this study we evaluated the acute toxicity of the combined treatment with chemoradiotherapy, according to the scheme of McDonald et al, in patients diagnosed with gastric cancer, after radical curative surgery.
  • METHODS: From July 2001 to December 2005, a total of 24 patients, with diagnosis of adenocarcinoma of the stomach or adenocarcinoma of the gastroesophageal junction, who were operated with total or subtotal gastrectomy with free resection margins, were treated at our service with a combined scheme of adjuvant chemoradiotherapy.
  • CONCLUSIONS: Combined treatment with chemoradiotherapy, according to the scheme of Macdonald, in diagnosed patients with gastric cancer, after radical curative surgery is a well tolerated treatment, with a low degree of acute toxicity, thus the treatment compliance is not difficult.
  • [MeSH-major] Adenocarcinoma / therapy. Stomach Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16952851.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


52. Mitsui F, Dobashi Y, Imoto I, Inazawa J, Kono K, Fujii H, Ooi A: Non-incidental coamplification of Myc and ERBB2, and Myc and EGFR, in gastric adenocarcinomas. Mod Pathol; 2007 Jun;20(6):622-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-incidental coamplification of Myc and ERBB2, and Myc and EGFR, in gastric adenocarcinomas.
  • This study was conducted to assess the frequencies of protein overexpression and gene amplification of Myc and to identify the mechanisms of Myc gene amplification, especially with regards to its possible coamplification with ERBB2 or EGFR in gastric adenocarcinomas.
  • By immunohistochemical analysis of a total of 300 formalin-fixed and paraffin-embedded gastric adenocarcinomas, the nuclear overexpression of MYC was found in 47 tumors (16%).
  • A fluorescence in situ hybridization (FISH) analysis revealed that nine (19%) of the 47 tumors with protein overexpression had cancer cells with high levels of Myc amplification, whereas only seven (6%) of the 122 tumors without protein overexpression showed high-level Myc gene amplification.
  • [MeSH-major] Adenocarcinoma / metabolism. Proto-Oncogene Proteins c-myc / biosynthesis. Receptor, Epidermal Growth Factor / biosynthesis. Receptor, ErbB-2 / biosynthesis. Stomach Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17431415.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-myc; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


53. Duan L, Wu AH, Sullivan-Halley J, Bernstein L: Nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric adenocarcinomas in Los Angeles County. Cancer Epidemiol Biomarkers Prev; 2008 Jan;17(1):126-34
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric adenocarcinomas in Los Angeles County.
  • BACKGROUND: Nonsteroidal anti-inflammatory drug (NSAID) use has been associated with a reduced risk of colon cancer; further epidemiologic data appear consistent for stomach and esophageal adenocarcinomas.
  • Yet, data on potential confounding effects by upper gastrointestinal tract (UGI) disorders on adenocarcinomas of the UGI are limited.
  • METHODS: This study recruited newly diagnosed patients with esophageal adenocarcinoma (n = 220), gastric cardia adenocarcinoma (n = 277), or distal gastric adenocarcinoma (n = 441) as well as 1,356 control subjects in Los Angeles County.
  • RESULTS: Duration of regular use of aspirin and non-aspirin NSAIDs was associated with reduced relative odds of distal gastric adenocarcinoma [>5 years use versus no regular use: odds ratio (OR), 0.61; 95% confidence interval, 0.40-0.92; P(trend) = 0.009] and esophageal adenocarcinoma (OR, 0.60; 95% confidence interval, 0.38-0.95; P(trend) = 0.04) in multivariable models that included history of UGI disorders and other potential confounding factors.
  • CONCLUSIONS: Results from this study support an inverse association between regular NSAID use and risk of esophageal and distal gastric adenocarcinomas in individuals with and without a history of UGI disorders with long duration and daily use, providing the greatest risk reduction.
  • [MeSH-major] Adenocarcinoma / epidemiology. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Esophageal Neoplasms / epidemiology. Stomach Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18187391.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / 5P30 ES 07048; United States / NCI NIH HHS / CA / CA 59636; United States / NCI NIH HHS / CN / N01 CN 25403
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal
  •  go-up   go-down


54. Bao G, Qiao Q, Zhao H, He X: Prognostic value of HMGB1 overexpression in resectable gastric adenocarcinomas. World J Surg Oncol; 2010;8:52
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of HMGB1 overexpression in resectable gastric adenocarcinomas.
  • In the present study, HMGB1 overexpression and its correlation with the clinicopathologic characteristics and recurrence-free survival were evaluated in gastric adenocarcinomas.
  • METHODS: 76 gastric adenocarcinomas surgically removed entered the study.
  • RESULTS: Almost all the gastric adenocarcinomas showed HMGB1 positive staining mainly in the nucleus, and the overexpression of HMGB1 was found in cancerous tissues with higher strong reactivity rate, compared with non-cancerous tissues (total expression score >or= 9, 42.0% vs. 9.0%, P < 0.001).
  • Survival analysis revealed that tumor stage negatively correlated with cancer-free survival (P = 0.022).
  • Furthermore, HMGB1 overexpression positively associated with cancer-free survival of resectable gastric adenocarcinomas (P = 0.023).
  • CONCLUSIONS: The overexpression of HMGB1 protein indicates that HMGB1 may play a role in the tumorigenesis of gastric adenocarcinomas.
  • And the overexpression of HMGB1 may be a marker of good prognosis of gastric adenocarcinoma given curative resection combined with adjuvant chemotherapy.
  • [MeSH-major] Adenocarcinoma / metabolism. HMGB1 Protein / metabolism. Stomach Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Lymphoma. 2008 Jun;49(6):1184-9 [18569640.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4026-30 [18519658.001]
  • [Cites] Cancer Res. 2008 Aug 15;68(16):6482-5 [18701469.001]
  • [Cites] Curr Opin Immunol. 2008 Oct;20(5):518-23 [18599281.001]
  • [Cites] Crit Care. 2008;12(4):168 [18671827.001]
  • [Cites] J Transl Med. 2009;7:38 [19476625.001]
  • [Cites] Biochim Biophys Acta. 2010 Jan-Feb;1799(1-2):131-40 [20123075.001]
  • [Cites] Pathobiology. 2010;77(1):17-23 [20185963.001]
  • [Cites] J Cancer Res Clin Oncol. 2010 May;136(5):677-84 [19898867.001]
  • [Cites] Curr Opin Investig Drugs. 2003 Dec;4(12):1405-9 [14763124.001]
  • [Cites] Science. 1999 Jul 9;285(5425):248-51 [10398600.001]
  • [Cites] Am J Pathol. 2005 Mar;166(3):751-60 [15743787.001]
  • [Cites] Gut. 2006 Feb;55(2):234-42 [16118352.001]
  • [Cites] Anticancer Res. 2007 Jan-Feb;27(1A):449-57 [17352266.001]
  • [Cites] Clin Cancer Res. 2007 May 15;13(10):2836-48 [17504981.001]
  • [Cites] J Biol Chem. 2007 Jun 15;282(24):17845-54 [17430886.001]
  • [Cites] Int J Mol Med. 2007 Aug;20(2):217-24 [17611640.001]
  • [Cites] J Immunother. 2007 Sep;30(6):596-606 [17667523.001]
  • [Cites] Am J Pathol. 2007 Sep;171(3):947-61 [17640970.001]
  • [Cites] Nat Med. 2007 Sep;13(9):1050-9 [17704786.001]
  • [Cites] Cancer Cell. 2007 Oct;12(4):300-1 [17936555.001]
  • [Cites] Immunol Rev. 2007 Dec;220:47-59 [17979839.001]
  • [Cites] Acta Pharmacol Sin. 2007 Dec;28(12):1957-67 [18031610.001]
  • [Cites] Curr Mol Med. 2007 Dec;7(8):725-34 [18331230.001]
  • [Cites] Curr Mol Med. 2007 Dec;7(8):777-89 [18331236.001]
  • [Cites] Angiogenesis. 2008;11(1):91-9 [18264787.001]
  • [Cites] Trends Mol Med. 2008 Apr;14(4):141-51 [18353726.001]
  • [Cites] Prostate. 2008 May 15;68(7):748-58 [18302220.001]
  • [Cites] Dig Liver Dis. 2008 Jun;40(6):446-52 [18294942.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10320-5 [18650382.001]
  • (PMID = 20579387.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HMGB1 Protein
  • [Other-IDs] NLM/ PMC2909949
  •  go-up   go-down


55. Jones KR, Whitmire JM, Merrell DS: A Tale of Two Toxins: Helicobacter Pylori CagA and VacA Modulate Host Pathways that Impact Disease. Front Microbiol; 2010;1:115

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Helicobacter pylori is a pathogenic bacterium that colonizes more than 50% of the world's population, which leads to a tremendous medical burden. H. pylori infection is associated with such varied diseases as gastritis, peptic ulcers, and two forms of gastric cancer: gastric adenocarcinoma and mucosa-associated lymphoid tissue lymphoma.
  • This association represents a novel paradigm for cancer development; H. pylori is currently the only bacterium to be recognized as a carcinogen.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Microbiol. 2007 Apr;9(4):952-61 [17140404.001]
  • [Cites] Oncogene. 2007 May 24;26(24):3462-72 [17160020.001]
  • [Cites] Infect Immun. 2007 Mar;75(3):1203-13 [17194805.001]
  • [Cites] Cell Microbiol. 2007 May;9(5):1148-61 [17217431.001]
  • [Cites] PLoS Pathog. 2008 May;4(5):e1000073 [18497859.001]
  • [Cites] J Biol Chem. 2008 Sep 26;283(39):26714-25 [18625712.001]
  • [Cites] J Med Microbiol. 2008 Sep;57(Pt 9):1062-7 [18719174.001]
  • [Cites] J Biol Chem. 2008 Oct 24;283(43):29367-74 [18772141.001]
  • [Cites] J Biol Chem. 2000 May 12;275(19):14009-12 [10747859.001]
  • [Cites] J Bacteriol. 2000 Jun;182(11):3278-80 [10809711.001]
  • [Cites] J Biol Chem. 2000 May 19;275(20):15200-6 [10809755.001]
  • [Cites] Infect Immun. 2000 Jun;68(6):3754-7 [10816542.001]
  • [Cites] Infect Immun. 2000 Jul;68(7):4354-7 [10858259.001]
  • [Cites] Development. 2000 Sep;127(17):3805-13 [10934025.001]
  • [Cites] Bioessays. 2000 Sep;22(9):818-26 [10944584.001]
  • [Cites] Annu Rev Microbiol. 2000;54:615-40 [11018139.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Nov 19;278(2):449-54 [11097857.001]
  • [Cites] EMBO J. 2000 Dec 1;19(23):6361-70 [11101509.001]
  • [Cites] J Exp Med. 2000 Dec 4;192(11):1601-10 [11104802.001]
  • [Cites] Infect Immun. 2001 Jan;69(1):543-6 [11119549.001]
  • [Cites] Infect Immun. 2001 Feb;69(2):1181-4 [11160018.001]
  • [Cites] J Clin Invest. 2001 Feb;107(3):363-70 [11160160.001]
  • [Cites] Eur J Clin Invest. 2001 Apr;31(4):344-8 [11298782.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Jun;2(6):457-66 [11389469.001]
  • [Cites] J Clin Microbiol. 2001 Jul;39(7):2463-5 [11427555.001]
  • [Cites] J Clin Invest. 2001 Sep;108(6):929-37 [11560962.001]
  • [Cites] Biochemistry. 2001 Oct 2;40(39):11887-96 [11570889.001]
  • [Cites] J Bacteriol. 2001 Nov;183(22):6499-508 [11673417.001]
  • [Cites] Jpn J Clin Oncol. 2001 Sep;31(9):471 [11689605.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2001 Dec;281(6):G1440-8 [11705749.001]
  • [Cites] Science. 2002 Jan 25;295(5555):683-6 [11743164.001]
  • [Cites] FEMS Microbiol Lett. 2002 Dec 17;217(2):231-6 [12480109.001]
  • [Cites] Cell Microbiol. 2003 Jan;5(1):25-40 [12542468.001]
  • [Cites] J Infect Dis. 2003 Jan 15;187(2):334-7 [12552462.001]
  • [Cites] EMBO J. 2003 Feb 3;22(3):515-28 [12554652.001]
  • [Cites] J Biol Chem. 2003 Apr 4;278(14):12101-8 [12562777.001]
  • [Cites] Nat Genet. 2003 Mar;33(3):375-81 [12598897.001]
  • [Cites] J Biol Chem. 2003 May 23;278(21):19183-9 [12626515.001]
  • [Cites] J Infect Dis. 2003 Apr 15;187(8):1165-77 [12695995.001]
  • [Cites] Nat Genet. 2003 Jun;34(2):148-50 [12717436.001]
  • [Cites] J Cell Biol. 2003 Apr 28;161(2):249-55 [12719469.001]
  • [Cites] J Biol Chem. 2003 Jul 11;278(28):25585-90 [12730232.001]
  • [Cites] J Biol Chem. 2003 Jul 18;278(29):26734-41 [12738773.001]
  • [Cites] Science. 2003 May 30;300(5624):1430-4 [12775840.001]
  • [Cites] Trends Biochem Sci. 2003 Jun;28(6):284-93 [12826400.001]
  • [Cites] Science. 2003 Aug 22;301(5636):1099-102 [12934009.001]
  • [Cites] J Biol Chem. 2003 Nov 28;278(48):48204-9 [13129933.001]
  • [Cites] J Biol Chem. 2004 Jan 16;279(3):2324-31 [14593124.001]
  • [Cites] Oncogene. 2003 Nov 13;22(51):8337-42 [14614457.001]
  • [Cites] J Biol Chem. 2004 Feb 20;279(8):7024-8 [14630932.001]
  • [Cites] Cell Microbiol. 2003 Dec;5(12):887-99 [14641174.001]
  • [Cites] J Exp Med. 2003 Dec 15;198(12):1887-97 [14676300.001]
  • [Cites] Cell Microbiol. 2004 Feb;6(2):143-54 [14706100.001]
  • [Cites] Cell Microbiol. 2004 Feb;6(2):167-74 [14706102.001]
  • [Cites] Gastroenterology. 2003 Dec;125(6):1636-44 [14724815.001]
  • [Cites] J Clin Invest. 2004 Feb;113(3):321-33 [14755326.001]
  • [Cites] J Biol Chem. 2004 Apr 23;279(17):17205-16 [14963045.001]
  • [Cites] J Infect Dis. 2004 Mar 1;189(5):820-7 [14976598.001]
  • [Cites] PLoS Pathog. 2010 Apr;6(4):e1000878 [20442789.001]
  • [Cites] Helicobacter. 2010 Jun;15(3):163-76 [20557357.001]
  • [Cites] Cancer Res. 2010 Jul 15;70(14):5740-8 [20587516.001]
  • [Cites] Dis Model Mech. 2010 Sep-Oct;3(9-10):605-17 [20682750.001]
  • [Cites] J Biol Chem. 1999 Apr 2;274(14):9277-82 [10092603.001]
  • [Cites] J Mol Biol. 1999 Jul 9;290(2):459-70 [10390344.001]
  • [Cites] Gastroenterology. 1999 Aug;117(2):342-9 [10419915.001]
  • [Cites] J Clin Microbiol. 1999 Sep;37(9):2979-82 [10449485.001]
  • [Cites] EMBO J. 1999 Oct 15;18(20):5517-27 [10523296.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12778-83 [10535999.001]
  • [Cites] J Immunol. 1999 Nov 15;163(10):5552-9 [10553083.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Dec 7;96(25):14559-64 [10588744.001]
  • [Cites] J Biol Chem. 1999 Dec 17;274(51):36693-9 [10593974.001]
  • [Cites] J Biol Chem. 1999 Dec 31;274(53):37736-42 [10608833.001]
  • [Cites] Gastroenterology. 2000 Jan;118(1):48-59 [10611153.001]
  • [Cites] J Exp Med. 2000 Jan 3;191(1):115-28 [10620610.001]
  • [Cites] Cancer Res. 1999 Dec 15;59(24):6124-31 [10626802.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Feb 1;97(3):1263-8 [10655519.001]
  • [Cites] Mol Cell Biol. 2000 Mar;20(5):1461-77 [10669724.001]
  • [Cites] Cell Signal. 2000 Jan;12(1):1-13 [10676842.001]
  • [Cites] Infect Immun. 2002 Jul;70(7):3824-32 [12065526.001]
  • [Cites] Cell Microbiol. 2002 Oct;4(10):677-90 [12366404.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14428-33 [12391297.001]
  • [Cites] Mol Cell. 2002 Oct;10(4):745-55 [12419219.001]
  • [Cites] J Biol Chem. 2003 Feb 7;278(6):3664-70 [12446738.001]
  • [Cites] Gastroenterology. 2002 Dec;123(6):1962-71 [12454853.001]
  • [Cites] J Exp Med. 1998 Jan 5;187(1):135-40 [9419220.001]
  • [Cites] Mol Microbiol. 1997 Nov;26(4):665-74 [9427397.001]
  • [Cites] J Physiol Pharmacol. 1997 Sep;48 Suppl 4:3-17 [9440051.001]
  • [Cites] J Immunol. 1998 Mar 1;160(5):2401-7 [9498783.001]
  • [Cites] Infect Immun. 2004 Jun;72(6):3646-9 [15155677.001]
  • [Cites] Gastroenterology. 2004 Aug;127(2):514-23 [15300584.001]
  • [Cites] Nat Rev Cancer. 2004 Sep;4(9):688-94 [15343275.001]
  • [Cites] J Infect Dis. 2004 Oct 15;190(8):1516-23 [15378446.001]
  • [Cites] Proteomics. 2004 Oct;4(10):2961-8 [15378755.001]
  • [Cites] J Biol Chem. 2004 Dec 3;279(49):51013-21 [15383529.001]
  • [Cites] Nat Immunol. 2004 Nov;5(11):1166-74 [15489856.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):8816-20 [15604238.001]
  • [Cites] J Cell Sci. 2005 Jan 15;118(Pt 2):313-22 [15615777.001]
  • [Cites] Curr Opin Microbiol. 2005 Feb;8(1):67-73 [15694859.001]
  • [Cites] Nat Rev Microbiol. 2005 Apr;3(4):320-32 [15759043.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Apr 5;102(14):5186-91 [15795379.001]
  • [Cites] Trends Microbiol. 2005 Apr;13(4):181-9 [15817388.001]
  • [Cites] J Biol Chem. 1992 May 25;267(15):10570-5 [1587837.001]
  • [Cites] Gastroenterology. 2005 May;128(5):1229-42 [15887107.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9300-5 [15972330.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9661-6 [15980153.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 26;102(30):10646-51 [16027366.001]
  • [Cites] Int J Cancer. 2006 Jan 1;118(1):203-8 [16032704.001]
  • [Cites] Mol Biol Cell. 2005 Oct;16(10):4852-66 [16055501.001]
  • [Cites] Toxicology. 2005 Nov 5;215(1-2):115-25 [16125295.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 8;102(45):16339-44 [16258069.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):5988-91 [15067113.001]
  • [Cites] Mol Cell. 2004 May 7;14(3):289-301 [15125833.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 May 18;101(20):7727-32 [15128946.001]
  • [Cites] Cancer Sci. 2004 May;95(5):442-7 [15132773.001]
  • [Cites] J Biol Chem. 2006 Apr 21;281(16):11250-9 [16436379.001]
  • [Cites] World J Gastroenterol. 2006 Jan 21;12(3):354-62 [16489633.001]
  • [Cites] Curr Cancer Drug Targets. 2006 Mar;6(2):107-21 [16529541.001]
  • [Cites] Gastroenterology. 2006 Apr;130(4):1181-90 [16618412.001]
  • [Cites] Br J Cancer. 2006 Sep 4;95(5):639-41 [16909137.001]
  • [Cites] J Pathol. 2006 Nov;210(3):306-14 [16933206.001]
  • [Cites] J Biol Chem. 2006 Oct 27;281(43):32344-52 [16954210.001]
  • [Cites] N Engl J Med. 1994 May 5;330(18):1267-71 [8145781.001]
  • [Cites] J Clin Pathol. 1995 Oct;48(10):967-9 [8537502.001]
  • [Cites] Infect Immun. 1996 Oct;64(10):4197-203 [8926088.001]
  • [Cites] Gut. 1997 Mar;40(3):297-301 [9135515.001]
  • [Cites] Oncogene. 2007 Jul 12;26(32):4617-26 [17237808.001]
  • [Cites] Gastroenterology. 2007 Apr;132(4):1309-19 [17408661.001]
  • [Cites] FEMS Immunol Med Microbiol. 2007 Jul;50(2):190-205 [17428306.001]
  • [Cites] J Cell Biol. 2007 Apr 23;177(2):343-54 [17438076.001]
  • [Cites] Nature. 2007 May 17;447(7142):330-3 [17507984.001]
  • [Cites] Infect Immun. 2007 Sep;75(9):4472-81 [17591797.001]
  • [Cites] Exp Cell Res. 2007 Oct 1;313(16):3459-71 [17692843.001]
  • [Cites] Gastroenterology. 2007 Sep;133(3):926-36 [17854597.001]
  • [Cites] J Immunol. 2007 Oct 15;179(8):5433-40 [17911630.001]
  • [Cites] Int J Cancer. 2008 Feb 15;122(4):823-31 [17960618.001]
  • [Cites] Cell Microbiol. 2008 Mar;10(3):781-94 [18005242.001]
  • [Cites] Cell Host Microbe. 2007 Oct 11;2(4):250-63 [18005743.001]
  • [Cites] Gastroenterology. 2008 Jan;134(1):306-23 [18166359.001]
  • [Cites] Cell Host Microbe. 2008 Jan 17;3(1):20-9 [18191791.001]
  • [Cites] Cancer Res. 2008 Jan 15;68(2):379-87 [18199531.001]
  • [Cites] J Med Microbiol. 2008 Feb;57(Pt 2):145-50 [18201978.001]
  • [Cites] Trends Microbiol. 2008 Mar;16(3):89-92 [18280164.001]
  • [Cites] J Immunol. 2008 Apr 1;180(7):5017-27 [18354227.001]
  • [Cites] Infect Immun. 2008 Jun;76(6):2296-303 [18362137.001]
  • [Cites] J Med Microbiol. 2008 May;57(Pt 5):554-62 [18436587.001]
  • [Cites] Gastroenterology. 2008 Jul;135(1):91-9 [18474244.001]
  • [Cites] PLoS Pathog. 2008 May;4(5):e1000064 [18483552.001]
  • [Cites] BMC Microbiol. 2009;9:36 [19216748.001]
  • [Cites] Gut Pathog. 2009;1(1):5 [19338650.001]
  • [Cites] Cell Host Microbe. 2009 Apr 23;5(4):397-403 [19380118.001]
  • [Cites] Gut Pathog. 2009;1(1):12 [19545429.001]
  • [Cites] Infect Immun. 2009 Sep;77(9):3782-90 [19546190.001]
  • [Cites] J Biol Chem. 2009 Aug 14;284(33):22166-72 [19546211.001]
  • [Cites] J Biol Chem. 2009 Aug 21;284(34):23024-36 [19553659.001]
  • [Cites] J Infect Dis. 2009 Sep 1;200(5):745-55 [19604117.001]
  • [Cites] J Clin Microbiol. 2009 Oct;47(10):3241-5 [19710266.001]
  • [Cites] Science. 2009 Aug 28;325(5944):1134-8 [19713527.001]
  • [Cites] PLoS Pathog. 2009 Oct;5(10):e1000603 [19798427.001]
  • [Cites] EMBO Rep. 2009 Nov;10(11):1242-9 [19820695.001]
  • [Cites] Clin Microbiol Infect. 2010 Aug;16(8):1264-9 [19832706.001]
  • [Cites] Cell Microbiol. 2010 Mar;12(3):372-85 [19888989.001]
  • [Cites] J Clin Microbiol. 2010 Feb;48(2):559-67 [19955279.001]
  • [Cites] BMJ. 1998 May 16;316(7143):1507-10 [9582144.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Jul 20;248(2):334-40 [9675136.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):10212-7 [9707626.001]
  • [Cites] J Clin Invest. 1998 Aug 15;102(4):813-20 [9710450.001]
  • [Cites] Gastroenterology. 1998 Sep;115(3):642-8 [9721161.001]
  • [Cites] Infect Immun. 1998 Dec;66(12):6014-6 [9826387.001]
  • [Cites] Microb Pathog. 1999 Jan;26(1):45-52 [9973580.001]
  • [Cites] J Neurochem. 1999 Jan;72(1):112-9 [9886061.001]
  • [Cites] J Biol Chem. 2002 Mar 1;277(9):6775-8 [11788577.001]
  • [Cites] Mol Microbiol. 2002 Feb;43(4):971-80 [11929545.001]
  • [Cites] J Infect Dis. 2002 Dec 1;186(11):1621-30 [12447739.001]
  • [Cites] Microbes Infect. 2003 Feb;5(2):143-50 [12650772.001]
  • [Cites] J Immunol. 2002 Mar 15;168(6):2603-7 [11884423.001]
  • [Cites] Mol Microbiol. 2001 Dec;42(5):1337-48 [11886563.001]
  • [Cites] Mol Microbiol. 2002 Mar;43(5):1243-53 [11918810.001]
  • [Cites] J Mol Biol. 2002 Apr 19;318(1):121-33 [12054773.001]
  • [Cites] Nat Struct Mol Biol. 2010 Jan;17(1):130-2 [19966800.001]
  • [Cites] J Immunol. 2009 Dec 15;183(12):8099-109 [20007577.001]
  • [Cites] J Clin Microbiol. 2010 Mar;48(3):690-6 [20053862.001]
  • [Cites] Ann Clin Microbiol Antimicrob. 2010;9:10 [20302630.001]
  • [Cites] J Biol Chem. 2010 May 21;285(21):16042-50 [20348091.001]
  • [Cites] J Clin Invest. 2010 May;120(5):1645-62 [20389019.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 2010 Jul;29(7):817-21 [20419465.001]
  • [Cites] J Natl Cancer Inst. 1997 Jun 18;89(12):863-8 [9196252.001]
  • [Cites] J Struct Biol. 1998 Jan;121(1):9-18 [9573616.001]
  • [Cites] Mol Microbiol. 1998 Apr;28(1):37-53 [9593295.001]
  • [Cites] Infect Immun. 1998 Oct;66(10):4856-66 [9746590.001]
  • [Cites] Cell Microbiol. 2009 Jan;11(1):70-82 [18782353.001]
  • [Cites] N Engl J Med. 1991 Oct 17;325(16):1127-31 [1891020.001]
  • [Cites] J Biol Chem. 2009 Jan 16;284(3):1612-9 [18996844.001]
  • [Cites] Cancer Sci. 2008 Oct;99(10):2004-11 [19016760.001]
  • [Cites] J Med Microbiol. 2008 Dec;57(Pt 12):1445-53 [19018013.001]
  • [Cites] Cell Microbiol. 2009 Mar;11(3):488-505 [19046339.001]
  • [Cites] J Infect Dis. 2009 Feb 15;199(4):505-12 [19099486.001]
  • [Cites] Cancer Res. 2009 Jan 15;69(2):632-9 [19147578.001]
  • [Cites] Cell Host Microbe. 2009 Jan 22;5(1):23-34 [19154985.001]
  • [Cites] J Clin Microbiol. 2009 Apr;47(4):959-68 [19158258.001]
  • [Cites] Autophagy. 2009 Apr;5(3):370-9 [19164948.001]
  • [Cites] J Infect Dis. 2009 Mar 1;199(5):641-51 [19199544.001]
  • [Cites] Lancet. 1992 Oct 17;340(8825):930-2 [1357347.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Jan;130(1):29-36 [14615935.001]
  • [Cites] Trends Genet. 2004 Apr;20(4):177-81 [15041171.001]
  • [Cites] Exp Mol Med. 2004 Dec 31;36(6):557-62 [15665589.001]
  • [Cites] Gastroenterology. 2005 Apr;128(4):833-48 [15825067.001]
  • [Cites] Cancer Sci. 2005 Dec;96(12):835-43 [16367902.001]
  • [Cites] Int J Cancer. 2006 Sep 15;119(6):1217-23 [16557568.001]
  • [Cites] Cell Microbiol. 2006 Nov;8(11):1740-52 [16759223.001]
  • [Cites] Lancet. 1991 Aug 10;338(8763):332-5 [1677696.001]
  • [Cites] J Gastroenterol. 2006 Jul;41(7):668-73 [16933004.001]
  • [Cites] J Immunol. 1992 Feb 15;148(4):1240-50 [1737937.001]
  • [Cites] Nucleic Acids Res. 1992 Jan 11;20(1):3-26 [1738600.001]
  • [Cites] Mol Carcinog. 2007 Sep;46(9):807-17 [17393422.001]
  • [Cites] J Natl Cancer Inst. 1991 Dec 4;83(23):1734-9 [1770552.001]
  • [Cites] J Korean Med Sci. 1991 Mar;6(1):7-14 [1888453.001]
  • [Cites] Rev Infect Dis. 1990 Jan-Feb;12 Suppl 1:S99-106 [2406864.001]
  • [Cites] J Med Microbiol. 1988 Jun;26(2):93-9 [3385767.001]
  • [Cites] Lancet. 1984 Jun 16;1(8390):1311-5 [6145023.001]
  • [Cites] J Natl Cancer Inst. 1995 Dec 6;87(23):1777-80 [7473834.001]
  • [Cites] J Biol Chem. 1995 Oct 13;270(41):23937-40 [7592587.001]
  • [Cites] J Biol Chem. 1995 Jul 28;270(30):17771-7 [7629077.001]
  • [Cites] Cancer Res. 1995 May 15;55(10):2111-5 [7743510.001]
  • [Cites] Infect Immun. 1995 Jan;63(1):94-8 [7806390.001]
  • [Cites] Immunol Today. 1994 Jun;15(6):274-81 [8068174.001]
  • [Cites] Microbiol Rev. 1993 Mar;57(1):50-108 [8096622.001]
  • [Cites] J Exp Med. 1994 May 1;179(5):1653-58 [8163943.001]
  • [Cites] Gut. 1993 Dec;34(12):1672-6 [8282253.001]
  • [Cites] Nature. 1993 May 6;363(6424):88-92 [8386805.001]
  • [Cites] Infect Immun. 1993 Apr;61(4):1427-31 [8454346.001]
  • [Cites] Infect Immun. 1993 May;61(5):1799-809 [8478069.001]
  • [Cites] Nature. 1993 May 6;363(6424):85-8 [8479541.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jun 15;90(12):5791-5 [8516329.001]
  • [Cites] Semin Oncol. 1996 Jun;23(3):281-91 [8658212.001]
  • [Cites] J Cell Biol. 1996 May;133(4):801-7 [8666665.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14648-53 [8962108.001]
  • [Cites] J Cell Biol. 1997 Aug 25;138(4):759-69 [9265644.001]
  • [Cites] J Biol Chem. 1997 Oct 3;272(40):25339-44 [9312153.001]
  • [Cites] J Exp Med. 2005 Nov 7;202(9):1235-47 [16275761.001]
  • [Cites] J Immunol. 2005 Dec 1;175(11):7162-9 [16301619.001]
  • [Cites] Mol Cell Biol. 2006 Jan;26(1):261-76 [16354697.001]
  • [Cites] Cell Microbiol. 2006 Jan;8(1):97-106 [16367869.001]
  • [Cites] EMBO Rep. 2010 Jan;11(1):10-1; author reply 11-2 [20033086.001]
  • [Cites] Cell Microbiol. 2010 Oct;12(10):1517-33 [20545942.001]
  • [Cites] J Mol Biol. 2010 Sep 3;401(5):792-8 [20615415.001]
  • [Cites] Lancet. 1989 May 27;1(8648):1167-8 [2566737.001]
  • [Cites] N Engl J Med. 1987 Feb 12;316(7):374-9 [3807974.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1994;61:177-240 [7715070.001]
  • [Cites] Blood. 1994 Oct 1;84(7):2243-52 [7919342.001]
  • (PMID = 21687723.001).
  • [ISSN] 1664-302X
  • [Journal-full-title] Frontiers in microbiology
  • [ISO-abbreviation] Front Microbiol
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / R01 AI065529
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Other-IDs] NLM/ PMC3109773
  • [Keywords] NOTNLM ; CagA / Helicobacter / VacA / cell-signaling / gastric cancer / toxin
  •  go-up   go-down


56. Furuya T, Uchiyama T, Adachi A, Chochi Y, Oga A, Kawauchi S, Ishiglo K, Sasaki K: Relation of DNA ploidy to genetic aberrations detected by chromosomal CGH and FISH in gastric adenocarcinomas. Oncol Rep; 2006 Jun;15(6):1491-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relation of DNA ploidy to genetic aberrations detected by chromosomal CGH and FISH in gastric adenocarcinomas.
  • We analyzed DNA copy number aberrations (DCNAs) by chromosomal comparative genomic hybridization (CGH) in 93 consecutive sporadic gastric adenocarcinomas.
  • Gastric cancers were divided on the basis of nuclear DNA content measured by laser scanning cytometry (LSC) into two groups, 36 DNA diploid (1.0 <or= DNA index (DI) < 1.2) and 57 aneuploid (DI >or= 1.2) cancers.
  • The diploid cancer group included nine subtype cancers that showed large numbers of DCNAs; the mean number of DCNAs detected by CGH was 26.7 per tumor.
  • The aneuploid cancer group included only three subtype tumors that showed only a small number of DCNAs (mean, 3 per tumor) and minimal intercellular variations in chromosomal copy number.
  • These data indicate that gastric adenocarcinomas can be divided into three types; aneuploid, major diploid type and diploid subtype cancers.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosome Aberrations. Ploidies. Stomach Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16685384.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


57. Lou F, Zhu YH, Pan HM: [Oxaliplatin combined with ELF regimen in the treatment of patients with advanced gastric cancer]. Zhonghua Zhong Liu Za Zhi; 2009 Jan;31(1):75-8
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Oxaliplatin combined with ELF regimen in the treatment of patients with advanced gastric cancer].
  • OBJECTIVE: To evaluate the efficacy and safety of the combination of oxaliplatin and ELF (VP16/CF/5-Fu) regimen in the treatment of patients with advanced gastric cancer.
  • All cases were pathologically confirmed as gastric cancer (adenocarcinoma in 57 cases and signet ring cell carcinoma in 12 cases).
  • CONCLUSION: This oxaliplatin combined with ELF regimen shows good efficacy and acceptable safety in advanced gastric cancer patients.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Signet Ring Cell / drug therapy. Organoplatinum Compounds / administration & dosage. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19538878.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 6PLQ3CP4P3 / Etoposide; 990S25980Y / Levoleucovorin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; ELF protocol
  •  go-up   go-down


58. Teh SK, Zheng W, Ho KY, Teh M, Yeoh KG, Huang Z: Near-infrared Raman spectroscopy for early diagnosis and typing of adenocarcinoma in the stomach. Br J Surg; 2010 Apr;97(4):550-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Near-infrared Raman spectroscopy for early diagnosis and typing of adenocarcinoma in the stomach.
  • BACKGROUND: The aim of this study was to evaluate the feasibility of using near-infrared (NIR) Raman spectroscopy for early diagnosis and typing of intestinal and diffuse adenocarcinoma of the stomach.
  • One hundred gastric tissue samples from 62 patients who underwent endoscopy or gastrectomy were used (70 normal tissue specimens and 30 adenocarcinomas).
  • RESULTS: High-quality Raman spectra ranging from 800 to 1800 cm(-1) were acquired from gastric tissue within 5 s.
  • There were significant differences in Raman spectra between normal stomach and the two gastric adenocarcinoma subtypes, particularly in the spectral ranges 850-1150, 1200-1500 and 1600-1750 cm(-1), which contain signals related to proteins, nucleic acids and lipids.
  • PCA-MNLR achieved predictive accuracies of 88, 92 and 94 per cent for normal stomach, and intestinal- and diffuse-type gastric adenocarcinomas respectively.
  • CONCLUSION: NIR Raman spectroscopy can detect gastric malignancy and identify the subtype of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Stomach Neoplasms / diagnosis
  • [MeSH-minor] Analysis of Variance. Early Detection of Cancer. Feasibility Studies. Female. Humans. Male. Middle Aged. Spectroscopy, Near-Infrared. Spectrum Analysis, Raman

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
  • (PMID = 20155786.001).
  • [ISSN] 1365-2168
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


59. Rüschoff J, Nagelmeier I, Baretton G, Dietel M, Höfler H, Schildhaus HU, Büttner R, Schlake W, Stoss O, Kreipe HH: [Her2 testing in gastric cancer. What is different in comparison to breast cancer?]. Pathologe; 2010 May;31(3):208-17
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Her2 testing in gastric cancer. What is different in comparison to breast cancer?].
  • Based on data from a large multicenter phase III trial (ToGA study) trastuzumab has very recently been approved by the EMEA for metastatic gastric cancer and adenocarcinoma of the gastro-esophageal junction.
  • However, testing of Her2 status by immunohistochemistry (IHC) differs from breast cancer in core aspects: 1.
  • Evaluation of Her2 in situ hybridization (ISH) is similar to breast cancer with ratio values of > or =2.0 indicating Her2 gene amplification.
  • Taking these modifications into account and defining the HER2 positive subgroup as IHC 3+ and IHC2+/FISH+, approximately 16% of gastric cancers are considered Her2 positive, affecting mainly tumor regions with intestinal (gland forming) type carcinoma.
  • In contrast to breast cancer, up to one-third of gastric cancers show a heterogeneous Her2 status both at IHC and ISH levels which favors bright field ISH over FISH.
  • [MeSH-major] Breast Neoplasms / genetics. Receptor, ErbB-2 / genetics. Stomach Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Algorithms. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Gene Amplification. Humans. In Situ Hybridization. In Situ Hybridization, Fluorescence. Neoplasm Metastasis


60. Azatian A, Yu H, Dai W, Schneiders FI, Botelho NK, Lord RV: Effectiveness of HSV-tk suicide gene therapy driven by the Grp78 stress-inducible promoter in esophagogastric junction and gastric adenocarcinomas. J Gastrointest Surg; 2009 Jun;13(6):1044-51
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effectiveness of HSV-tk suicide gene therapy driven by the Grp78 stress-inducible promoter in esophagogastric junction and gastric adenocarcinomas.
  • This study investigated the effectiveness of HSV-tk activation as gene therapy for gastroesophageal junction and gastric adenocarcinomas using either the stress-inducible Grp78 promoter or the murine leukemia virus long-terminal repeat (LTR) promoter.
  • METHODS: The HSV-tk gene, controlled by either the Grp78 promoter or the LTR promoter, was transduced into the gastroesophageal junction adenocarcinoma cell line SK-GT-5 and the gastric adenocarcinoma cell line MKN-74.
  • CONCLUSION: HSV-tk xwith ganciclovir suicide gene therapy results in significant cell killing in gastroesophageal junction and gastric adenocarcinoma cells both in vitro and in vivo, but complete tumor elimination only occurred with the gastric adenocarcinoma cell tumors.
  • [MeSH-major] Adenocarcinoma / therapy. Genes, Transgenic, Suicide / genetics. Genetic Therapy / methods. Heat-Shock Proteins / genetics. Stomach Neoplasms / therapy. Thymidine Kinase / genetics

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. GANCICLOVIR .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19277794.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Heat-Shock Proteins; 0 / molecular chaperone GRP78; EC 2.7.1.21 / Thymidine Kinase; P9G3CKZ4P5 / Ganciclovir
  •  go-up   go-down


61. Zali H, Rezaei-Tavirani M, Kariminia A, Yousefi R, Shokrgozar MA: Evaluation of growth inhibitory and apoptosis inducing activity of human calprotectin on the human gastric cell line (AGS). Iran Biomed J; 2008 01;12(1):7-14
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of growth inhibitory and apoptosis inducing activity of human calprotectin on the human gastric cell line (AGS).
  • In previous studies, cytotoxicity and apoptotic effects of calprotectin are shown on different cancer cell lines, but not human gastric cancer cell lines.
  • In the present study, cytotoxicity and apoptotic effects of calprotectin on human gastric adenocarcinoma cancer cell line (AGS) were evaluated.
  • [MeSH-major] Adenocarcinoma / drug therapy. Apoptosis / drug effects. Leukocyte L1 Antigen Complex / pharmacology. Stomach Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18392090.001).
  • [ISSN] 1028-852X
  • [Journal-full-title] Iranian biomedical journal
  • [ISO-abbreviation] Iran. Biomed. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Iran
  • [Chemical-registry-number] 0 / Annexin A5; 0 / Leukocyte L1 Antigen Complex
  • [Keywords] NOTNLM ; Human calprotectin / Human gastric adenocarcinoma / Growth inhibition / Apoptosis
  •  go-up   go-down


62. Ma X, Chen K, Huang S, Zhang X, Adegboyega PA, Evers BM, Zhang H, Xie J: Frequent activation of the hedgehog pathway in advanced gastric adenocarcinomas. Carcinogenesis; 2005 Oct;26(10):1698-705
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent activation of the hedgehog pathway in advanced gastric adenocarcinomas.
  • Recent studies indicate that the hedgehog pathway activation occurs in the stomach and other gastrointestinal cancers.
  • Here, we report our findings that the elevated expression of hedgehog target genes human patched gene 1 (PTCH1) or Gli1 occurs in 63 of the 99 primary gastric cancers.
  • The sonic hedgehog (Shh) transcript is localized to the cancer tissue, whereas expression of Gli1 and PTCH1 is observed both in the cancer and in the surrounding stroma.
  • Treatment of gastric cancer cells with KAAD-cyclopamine, a hedgehog signaling inhibitor, decreases expression of Gli1 and PTCH1, resulting in cell growth inhibition and apoptosis.
  • Thus, our analysis of in vivo tissues indicates that the hedgehog pathway is frequently activated in advanced gastric adenocarcinomas; our in vitro studies suggest that hedgehog signaling contributes to gastric cancer cell growth.
  • These data predict that targeted inhibition of the hedgehog pathway may be effective in the prevention and treatment of advanced gastric adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / pathology. Stomach Neoplasms / pathology. Trans-Activators / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15905200.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA94160
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Gli protein; 0 / Hedgehog Proteins; 0 / Oncogene Proteins; 0 / Receptors, Cell Surface; 0 / SHH protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / patched receptors
  •  go-up   go-down


63. Hayashi K, Sengoku N, Kosaka Y, Enomoto T, Kajita S, Kondo Y, Kuranami M, Watanabe M: [A long-term survival case of progressive breast cancer detected in gastric metastasis]. Gan To Kagaku Ryoho; 2010 Nov;37(12):2756-9
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A long-term survival case of progressive breast cancer detected in gastric metastasis].
  • A 51-year-old postmenopausal woman was diagnosed as having adenocarcinoma (gastric cancer type 4) from gastric biopsy by upper endoscopy.
  • After gastric biopsy, tissues are stained by ER and PgR in immunohistochemistry.
  • The diagnosis was modified from gastric cancer to T2N1M1, stage IV left breast cancer, accompanied by a treatment.
  • Metastatic gastric tumors simulating type 4 advanced gastric cancer (MGTS type 4) and invasive lobular carcinoma are known to have an unfavorable prognosis.
  • We should keep in mind a possibility of gastric metastasis of breast cancer, when consulting a female patient with gastric cancer type 4.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / pathology. Stomach Neoplasms / secondary

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21224703.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 3Z8479ZZ5X / Epirubicin; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


64. Wronski M, Ziarkiewicz-Wroblewska B, Gornicka B, Cebulski W, Slodkowski M, Wasiutynski A, Krasnodebski IW: Synchronous occurrence of gastrointestinal stromal tumors and other primary gastrointestinal neoplasms. World J Gastroenterol; 2006 Sep 7;12(33):5360-2
Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The synchronous stromal tumors were located in the stomach and were incidentally found during the operation.
  • The coexistent neoplasms were colon adenocarcinoma, gastric cancer (2 cases) and gastric lymphoma.
  • [MeSH-major] Gastrointestinal Neoplasms / diagnosis. Gastrointestinal Stromal Tumors / diagnosis. Neoplasms, Second Primary / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 2000 May;124(5):682-6 [10782147.001]
  • [Cites] Hum Pathol. 2002 May;33(5):459-65 [12094370.001]
  • [Cites] J Gastroenterol Hepatol. 2002 Sep;17(9):1033-6 [12167128.001]
  • [Cites] Med Sci Monit. 2004 Aug;10(8):LE13-4 [15278004.001]
  • [Cites] World J Gastroenterol. 2006 Feb 7;12(5):815-7 [16521203.001]
  • [Cites] Cancer. 1984 Mar 1;53(5):1088-92 [6692300.001]
  • [Cites] Nat Genet. 1998 Aug;19(4):323-4 [9697690.001]
  • [Cites] Mayo Clin Proc. 1999 Jun;74(6):543-52 [10377927.001]
  • [Cites] Pol J Pathol. 2005;56(2):51-61 [16092666.001]
  • [Cites] Cancer Res. 1970 Feb;30(2):455-65 [5458974.001]
  • (PMID = 16981268.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Other-IDs] NLM/ PMC4088205
  •  go-up   go-down


65. Saad N, Hot A, Ninet J, Claudy A, Faure M: [Acquired hypertrichosis lanuginosa and gastric adenocarcinoma]. Ann Dermatol Venereol; 2007 Jan;134(1):55-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acquired hypertrichosis lanuginosa and gastric adenocarcinoma].
  • [Transliterated title] Hypertrichose lanugineuse acquise et adénocarcinome gastrique.
  • We report a case in which this hypertrichosis allowed diagnosis of gastric cancer.
  • Clinical examination led to diagnosis of acquired hypertrichosis lanuginosa, which subsequently resulted in the discovery of gastric adenocarcinoma.
  • Our finding is original since it is the first recorded case of association with gastric adenocarcinoma.
  • Two hypotheses have nevertheless been suggested: acquired hypertrichosis lanuginosa could be associated with secretion by the tumour of an as yet unidentified serum factor, or with a nutritional deficiency that may accompany this form of cancer.
  • [MeSH-major] Adenocarcinoma / complications. Hypertrichosis / etiology. Paraneoplastic Syndromes / etiology. Stomach Neoplasms / complications

  • Genetic Alliance. consumer health - Hypertrichosis lanuginosa, acquired.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17384545.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


66. Bazuro GE, Torino F, Gasparini G, Capurso L: Chemoprevention in gastrointestinal adenocarcinoma: for few but not for all? Minerva Gastroenterol Dietol; 2008 Dec;54(4):429-44
Hazardous Substances Data Bank. MESALAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemoprevention in gastrointestinal adenocarcinoma: for few but not for all?
  • Despite the general progress of the last two decades in oncogenesis mechanism comprehension, in screening and surveillance programs, in technological support to diagnosis and in treatment protocols, the long-term survival of gastrointestinal (GI) cancer patients is not substantially changed.
  • Therefore chemoprevention strategies still appear as a possible alternative to screening and surveillance programs in reducing the incidence and the mortality for GI cancer, at an acceptable cost/effectiveness ratio.
  • The present review is focused on three GI cancers: esophageal adenocarcinoma, gastric cancer and colorectal cancer and their respective precarcinogenic lesions.
  • The authors examine, for each neoplasia, the available chemopreventive agents, their mechanism of action in preventing cancer, the potential targets in the cell growth process, the cost/effectiveness ratio and, whenever present in literature, a comparison with other cancer prevention strategies.
  • The authors conclude that, at present, with the available agents, chemoprevention is not indicated for all patients at low or moderate risk for GI cancer, and should not be considered as a substitute for endoscopic surveillance.
  • In future more specific agents and combined therapies should be tested in specific group of patients identified by their genomic susceptibility to develop cancer and responsiveness to therapy.
  • [MeSH-major] Adenocarcinoma / prevention & control. Gastrointestinal Neoplasms / prevention & control
  • [MeSH-minor] Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Aspirin / therapeutic use. Colorectal Neoplasms / prevention & control. Esophageal Neoplasms / prevention & control. Humans. Mesalamine / therapeutic use. Probiotics / therapeutic use. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Stomach Neoplasms / prevention & control

  • Hazardous Substances Data Bank. ACETYLSALICYLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19047983.001).
  • [ISSN] 1121-421X
  • [Journal-full-title] Minerva gastroenterologica e dietologica
  • [ISO-abbreviation] Minerva Gastroenterol Dietol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 4Q81I59GXC / Mesalamine; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; R16CO5Y76E / Aspirin
  • [Number-of-references] 102
  •  go-up   go-down


67. Zintzaras E: Association of methylenetetrahydrofolate reductase (MTHFR) polymorphisms with genetic susceptibility to gastric cancer: a meta-analysis. J Hum Genet; 2006;51(7):618-24
Nature Publishing Group. Nature Publishing Group (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of methylenetetrahydrofolate reductase (MTHFR) polymorphisms with genetic susceptibility to gastric cancer: a meta-analysis.
  • To clarify the influence of MTHFR C677T and A1298C polymorphisms on gastric cancer (GC), a meta-analysis of eight case-control studies (1,584/2,785 cases/controls) was carried out.
  • Regarding gastric cancer adenocarcinoma (GCA), an association for the allele contrast in East Asians was detected: fixed effects (FE) OR=1.36 (1.18-1.56).
  • [MeSH-major] Adenocarcinoma / genetics. Genetic Predisposition to Disease. Methylenetetrahydrofolate Reductase (NADPH2) / genetics. Polymorphism, Genetic. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16758123.001).
  • [ISSN] 1434-5161
  • [Journal-full-title] Journal of human genetics
  • [ISO-abbreviation] J. Hum. Genet.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Meta-Analysis
  • [Publication-country] Japan
  • [Chemical-registry-number] EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2)
  •  go-up   go-down


68. Solomon NL, Cheung MC, Byrne MM, Zhuge Y, Franceschi D, Livingstone AS, Koniaris LG: Does chemoradiotherapy improve outcomes for surgically resected adenocarcinoma of the stomach or esophagus? Ann Surg Oncol; 2010 Jan;17(1):98-108
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does chemoradiotherapy improve outcomes for surgically resected adenocarcinoma of the stomach or esophagus?
  • BACKGROUND: To use a population-based registry to evaluate the effect of chemotherapy or radiation on survival for patients undergoing curative-intent surgery for adenocarcinoma of the esophagus or stomach.
  • METHODS: A linked data set between the Florida Cancer Data System and the Florida Agency for Health Care Administration from 1998 to 2003 was queried.
  • RESULTS: Overall, 3,378 patients underwent surgical extirpation with curative intent, 636 patients had esophageal adenocarcinoma (EAC), and 2,742 patients had gastric adenocarcinoma (GAC).
  • A small improvement in survival was observed with adjuvant therapies for GAC.
  • For localized EAC or GAC there was no additional survival benefit associated with adjuvant therapies.
  • For GAC, patients with regional disease showed an improved median survival with chemotherapy (21.1 vs. 11.2 months, P < .001) and radiotherapy (22.6 vs. 12.3 months, P < .001).
  • In multivariate analysis, independent predictors of improved survival for regional GAC include chemotherapy (HR .629, P < .001) and radiation (HR .603, P < .001).
  • CONCLUSIONS: Patients with regional adenocarcinoma of the esophagus or stomach, but not those with localized disease, derive a statistically significant survival benefit from the addition of chemotherapy and radiation to surgical resection.
  • [MeSH-major] Adenocarcinoma / therapy. Esophageal Neoplasms / therapy. Stomach Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2010 Jun;17(6):1715-6; author reply 1717 [20339949.001]
  • (PMID = 19777191.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


69. Papaioannides D, Korantzopoulos P, Bouropoulos C, Latsi P, Fotinou M, Orphanidou D: Microscopic polyangiitis complicated by the development of prostate cancer and flutamide-induced hepatitis. Int Urol Nephrol; 2005;37(3):515-20
MedlinePlus Health Information. consumer health - Vasculitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microscopic polyangiitis complicated by the development of prostate cancer and flutamide-induced hepatitis.
  • We report a case of a 65-year-old man with microscopic polyangiitis who developed prostate cancer and gastric adenocarcinoma after prolonged oral use of cyclophosphamide.
  • It is suggested that patients with vasculitis or other autoimmune disorders should avoid prolonged use of cyclophosphamide and other cytotoxic drugs in order to minimize long-term adverse effects, of which the risk of cancer is by far the most important.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Hormonal / adverse effects. Flutamide / adverse effects. Prostatic Neoplasms / drug therapy. Vasculitis / diagnosis
  • [MeSH-minor] Aged. Humans. Male. Stomach Neoplasms / secondary


70. Li LG, Xu HM: Inducible nitric oxide synthase, nitrotyrosine and apoptosis in gastric adenocarcinomas and their correlation with a poor survival. World J Gastroenterol; 2005 May 7;11(17):2539-44
Hazardous Substances Data Bank. L-TYROSINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inducible nitric oxide synthase, nitrotyrosine and apoptosis in gastric adenocarcinomas and their correlation with a poor survival.
  • AIM: To detect the presence of inducible nitric oxide synthase (iNOS), nitrotyrosine (NT) and apoptosis in gastric adenocarcinomas and their possible correlations with the clinicopathological characteristics and prognosis of gastric adenocarcinoma.
  • METHODS: Sixty-six specimens of gastric adenocarcinoma and corresponding adjacent normal gastric tissues were studied.
  • RESULTS: Results showed that iNOS expression was detected at an intermediate or high level in 41 of 66 (62%) specimens of gastric adenocarcinoma.
  • Neither of them was found in the normal gastric tissues; there were significant positive correlations among iNOS expression, NT expression and AI.
  • Many clinicopathologic characteristics of gastric adenocarcinoma, such as tumor size, depth of invasion, lymph node metastasis and TNM staging, were related to iNOS and NT expressions (P<0.05).
  • CONCLUSION: NO produced by iNOS may play a stronger role in promoting gastric adenocarcinoma growth than in suppressing its growth. iNOS and NT expressions by gastric adenocarcinoma may correlate with a poor survival.
  • [MeSH-major] Adenocarcinoma / metabolism. Apoptosis. Nitric Oxide Synthase / metabolism. Stomach Neoplasms / metabolism. Tyrosine / analogs & derivatives. Tyrosine / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15849807.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 31C4KY9ESH / Nitric Oxide; 3604-79-3 / 3-nitrotyrosine; 42HK56048U / Tyrosine; EC 1.14.13.39 / NOS2 protein, human; EC 1.14.13.39 / Nitric Oxide Synthase; EC 1.14.13.39 / Nitric Oxide Synthase Type II
  • [Other-IDs] NLM/ PMC4305739
  •  go-up   go-down


71. Gümüs-Akay G, Unal AE, Elhan AH, Bayar S, Karadayt K, Sunguroglu A, Kadikiran A, Tükün A: DNA copy number changes in gastric adenocarcinomas: high resolution-comparative genomic hybridization study in Turkey. Arch Med Res; 2009 Oct;40(7):551-60
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA copy number changes in gastric adenocarcinomas: high resolution-comparative genomic hybridization study in Turkey.
  • BACKGROUND AND AIMS: Multiple genetic alterations are responsible for development and progression of gastric cancer which is one of the leading causes of cancer-related deaths worldwide.
  • The aim of this study was to identify the genomic imbalances of gains and/or losses in gastric adenocarcinomas from Turkish patients and to investigate their association with development and progression of this type of cancer.
  • METHODS: Forty three patients with gastric adenocarcinoma were enrolled in this study and genomic imbalances were analyzed by high-resolution-comparative genomic hybridization (HR-CGH).
  • RESULTS: In 36/43 cases (84%) of gastric adenocarcinomas, genomic imbalances have involved all chromosomes in various combinations.
  • CONCLUSIONS: A series of gains, losses and amplifications concerned with gastric adenocarcinoma identified in this study are presented in detail.
  • [MeSH-major] Adenocarcinoma / genetics. Comparative Genomic Hybridization / methods. DNA Copy Number Variations. Stomach Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 IMSS. Published by Elsevier Inc.
  • (PMID = 20082868.001).
  • [ISSN] 1873-5487
  • [Journal-full-title] Archives of medical research
  • [ISO-abbreviation] Arch. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


72. Baba H, Fujiwara N, Nakamura H, Tanaka K, Kuwabara H, Tamai S, Nakajima K, Goseki N, Shimoda S: [Adjuvant chemotherapy of S-1 and CDDP for undifferentiated adenocarcinoma of the stomach]. Gan To Kagaku Ryoho; 2008 Nov;35(12):2051-3
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adjuvant chemotherapy of S-1 and CDDP for undifferentiated adenocarcinoma of the stomach].
  • Gastrointestinal endoscopy revealed a giant ulcer at distal portion of the stomach.
  • Final pathology report was undifferentiated adenocarcinoma of the stomach, exposing itself to serosa with lymph node metastasis.
  • Undifferentiated adenocarcinoma of the stomach is rare disease.
  • Immunohistochemical staining is useful for a differential diagnosis.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Oxonic Acid / therapeutic use. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology. Tegafur / therapeutic use

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106520.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


73. Gálvez-Muñoz E, Gallego-Plazas J, Gonzalez-Orozco V, Menarguez-Pina F, Ruiz-Maciá JA, Morcillo MA: Hepatoid adenocarcinoma of the stomach - a different histology for not so different gastric adenocarcinoma: a case report. Int Semin Surg Oncol; 2009;6:13

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatoid adenocarcinoma of the stomach - a different histology for not so different gastric adenocarcinoma: a case report.
  • Hepatoid adenocarcinoma is an extrahepatic tumor characterized by morphological similarities to hepatocellular carcinoma.
  • Hepatoid adenocarcinoma of the stomach is a cancer with an extremely poor prognosis with few cases reported.
  • Gastric biopsies of the tumor revealed poorly differenciated adenocarcinoma, with hepatoid differentiation.
  • After a diagnosis of AFP-producing hepatoid adenocarcinoma of the stomach with multiple liver metastases was made, pallitive total gastrectomy, without liver resection, was performed.
  • Accurate diagnosis of hepatoid adenocarcinoma of the stomach is important, and should be suspected under certain circumstances.
  • We describe this rare case of hepatoid adenocarcinoma of the stomach, and review the literature concerning the clinicopathological aspects.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2006 Jan;30(1):21-7 [16369718.001]
  • [Cites] Gastric Cancer. 2001;4(1):43-52 [11706627.001]
  • [Cites] J Surg Oncol. 1998 Sep;69(1):41-4 [9762890.001]
  • [Cites] J Urol. 1994 Sep;152(3):958-60 [7519684.001]
  • [Cites] Cancer. 1993 Jan 15;71(2):293-6 [7678544.001]
  • [Cites] Gastroenterol Jpn. 1992 Dec;27(6):785-91 [1281798.001]
  • [Cites] Ann Thorac Surg. 1992 Jan;53(1):151-2 [1370196.001]
  • [Cites] Cancer. 1991 Nov 1;68(9):1863-8 [1717128.001]
  • [Cites] Cancer. 1986 Jul 1;58(1):119-26 [2423220.001]
  • [Cites] Cancer. 1988 Nov 1;62(9):1994-8 [2458825.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):840-8 [2410093.001]
  • [Cites] Cancer. 1981 Oct 1;48(7):1647-55 [6169423.001]
  • [Cites] Ann Oncol. 2008 Aug;19(8):1450-7 [18558665.001]
  • [Cites] Anticancer Res. 2008 Mar-Apr;28(2B):1309-15 [18505071.001]
  • [Cites] Surg Oncol. 2007 Dec;16(4):267-75 [17881220.001]
  • [Cites] Hum Pathol. 2007 Jun;38(6):857-63 [17320150.001]
  • [Cites] J Dig Dis. 2007 Feb;8(1):23-8 [17261131.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):4991-7 [17075117.001]
  • [Cites] ANZ J Surg. 2006 Jan-Feb;76(1-2):60-3 [16483298.001]
  • [Cites] Cancer Res. 1972 May;32(5):979-82 [4111729.001]
  • [Cites] N Engl J Med. 1971 Nov 4;285(19):1060-1 [4106199.001]
  • [Cites] Cancer Res. 1968 Jul;28(7):1344-50 [4174340.001]
  • [Cites] Cancer Res. 1975 Apr;35(4):991-6 [46783.001]
  • [Cites] Cancer. 1970 Jun;25(6):1261-70 [4987264.001]
  • [Cites] Am J Surg. 2004 Apr;187(4):543-6 [15041508.001]
  • [Cites] Br J Surg. 2002 Nov;89(11):1438-43 [12390389.001]
  • [Cites] Ann Oncol. 2004 Nov;15(11):1585-95 [15520058.001]
  • (PMID = 19674468.001).
  • [ISSN] 1477-7800
  • [Journal-full-title] International seminars in surgical oncology : ISSO
  • [ISO-abbreviation] Int Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2731104
  •  go-up   go-down


74. Kojima K, Kishimoto T, Nagai Y, Tanizawa T, Nakatani Y, Miyazaki M, Ishikura H: The expression of hepatocyte nuclear factor-4alpha, a developmental regulator of visceral endoderm, correlates with the intestinal phenotype of gastric adenocarcinomas. Pathology; 2006 Dec;38(6):548-54
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The expression of hepatocyte nuclear factor-4alpha, a developmental regulator of visceral endoderm, correlates with the intestinal phenotype of gastric adenocarcinomas.
  • However, adult gastric mucosa does not express HNF-4alpha.
  • We investigated the possible involvement of HNF-4alpha in intestinal metaplasia and the intestinalisation of gastric adenocarcinomas.
  • METHODS: Thirty-five cases of adenocarcinomas and 46 cases of adjacent non-neoplastic mucosa with (22 lesions) or without (24 lesions) intestinal metaplasia were immunostained for HNF-4alpha.
  • The gastric or the intestinal phenotype was also examined using immunohistochemistry for MUC5AC, MUC2, CD10, and gastric-type mucin (GTM).
  • Adenocarcinomas were classified into the gastric type (G-type, 42.9%), the mixed gastric and intestinal type (GI-type, 31.4%), and the intestinal type (I-type, 25.7%).
  • All adenocarcinomas more or less expressed HNF-4alpha, with an intense expression being seen in the I-type (p<0.01) and in well-differentiated adenocarcinomas (p<0.03).
  • CONCLUSIONS: HNF-4alpha expression is associated with the intestinal phenotype of non-neoplastic and neoplastic gastric glandular cells, suggesting a possible involvement in the establishment and/or maintenance of the intestinal phenotype of the gastric mucosa and adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / pathology. Endoderm / physiology. Hepatocyte Nuclear Factor 4 / metabolism. Intestines / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Gastric Mucosa / embryology. Gastric Mucosa / pathology. Gene Expression Regulation, Neoplastic. Humans. Phenotype

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17393984.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HNF4A protein, human; 0 / Hepatocyte Nuclear Factor 4
  •  go-up   go-down


75. Shibata T, Noguchi T, Takeno S, Gabbert HE, Ramp U, Kawahara K: Disturbed XIAP and XAF1 expression balance is an independent prognostic factor in gastric adenocarcinomas. Ann Surg Oncol; 2008 Dec;15(12):3579-87
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disturbed XIAP and XAF1 expression balance is an independent prognostic factor in gastric adenocarcinomas.
  • However, little research has been conducted on the association between gastric cancer survival and the mechanism of apoptosis involving XIAP and its antagonists, Smac/DIABLO and XAF1.
  • METHODS: XIAP, Smac/DIABLO, and XAF1 expression was analyzed by immunohistochemistry (IHC) in 187 gastric adenocarcinomas.
  • CONCLUSION: The expression balance of XIAP and XAF1 is an independent prognostic factor in gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / metabolism. Intracellular Signaling Peptides and Proteins / metabolism. Mitochondrial Proteins / metabolism. Neoplasm Proteins / metabolism. Stomach Neoplasms / metabolism. X-Linked Inhibitor of Apoptosis Protein / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18807090.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DIABLO protein, human; 0 / Intracellular Signaling Peptides and Proteins; 0 / Mitochondrial Proteins; 0 / Neoplasm Proteins; 0 / X-Linked Inhibitor of Apoptosis Protein; 0 / XAF1 protein, human; 0 / XIAP protein, human
  •  go-up   go-down


76. Alves MK, Lima VP, Ferrasi AC, Rodrigues MA, De Moura Campos Pardini MI, Rabenhorst SH: CDKN2A promoter methylation is related to the tumor location and histological subtype and associated with Helicobacter pylori flaA(+) strains in gastric adenocarcinomas. APMIS; 2010 Apr;118(4):297-307
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CDKN2A promoter methylation is related to the tumor location and histological subtype and associated with Helicobacter pylori flaA(+) strains in gastric adenocarcinomas.
  • Therefore, we examined a series of gastric adenocarcinomas to assess the association between p16INK4A inactivation and H. pylori genotype (vacA, cagA, cagE, virB11 and flaA) according to the location and histological subtype of the tumors. p16INK4A expression and CDKN2A promoter methylation were found in 77 gastric adenocarcinoma samples by immunohistochemistry and methylation-specific PCR, respectively.
  • The present data suggest that there is a differential influence and relevance of H. pylori genotype in gastric cancer development.
  • [MeSH-major] Adenocarcinoma / genetics. Genes, p16. Helicobacter Infections / genetics. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20402675.001).
  • [ISSN] 1600-0463
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16
  •  go-up   go-down


77. Ward MH, Heineman EF, Markin RS, Weisenburger DD: Adenocarcinoma of the stomach and esophagus and drinking water and dietary sources of nitrate and nitrite. Int J Occup Environ Health; 2008 Jul-Sep;14(3):193-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the stomach and esophagus and drinking water and dietary sources of nitrate and nitrite.
  • We conducted a population-based case-control study of adenocarcinoma of the stomach and esophagus in Nebraska, U.S.A.
  • Among those who primarily used public water supplies (79 distal stomach, 84 esophagus, 321 controls), average nitrate levels were not associated with risk (highest versus lowest quartile: stomach OR=1.2, 95% CI [0.5-2.7]; esophagus OR=1.3, 95% CI [0.6-3.1]).
  • We observed the highest ORs for distal stomach cancer among those with higher water nitrate ingestion and higher intake of processed meat compared with low intakes of both; however, the test for positive interaction was not significant (p=0.213).
  • We did not observe this pattern for esophagus cancer.
  • Increasing intake of nitrate and nitrite from animal sources was associated with elevated ORs for stomach cancer and with a significant positive trend in risk of esophagus cancer (P-trend=0.325 and 0.015, respectively).
  • [MeSH-major] Adenocarcinoma / epidemiology. Diet / adverse effects. Esophageal Neoplasms / epidemiology. Nitrates / analysis. Nitrites / analysis. Stomach Neoplasms / epidemiology. Water Supply / analysis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Causes Control. 2001 Feb;12(2):163-72 [11246845.001]
  • [Cites] Nutr Cancer. 2007;59(2):185-91 [18001213.001]
  • [Cites] Nutr Cancer. 2002;42(1):33-40 [12235648.001]
  • [Cites] J Nutr. 2002 Nov;132(11 Suppl):3522S-3525S [12421881.001]
  • [Cites] Cancer Res. 1989 Jun 1;49(11):3117-21 [2720669.001]
  • [Cites] Epidemiology. 1990 Sep;1(5):349-56 [2078610.001]
  • [Cites] Epidemiology. 1990 Jan;1(1):58-64 [2081241.001]
  • [Cites] Arch Environ Health. 1992 Jul-Aug;47(4):292-4 [1497383.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1992 Sep-Oct;1(6):455-61 [1302557.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1995 Jan-Feb;4(1):29-36 [7894321.001]
  • [Cites] Int J Cancer. 1997 Mar 28;71(1):14-9 [9096659.001]
  • [Cites] Br J Cancer. 1998 Jul;78(1):129-35 [9662263.001]
  • [Cites] Environ Health Perspect. 1998 Aug;106(8):459-63 [9681972.001]
  • [Cites] Int J Cancer. 1999 Mar 15;80(6):852-6 [10074917.001]
  • [Cites] Environ Health Perspect. 2005 Nov;113(11):1607-14 [16263519.001]
  • [Cites] J Occup Environ Med. 2005 Dec;47(12):1260-7 [16340707.001]
  • [Cites] Carcinogenesis. 2006 Jul;27(7):1497-501 [16571648.001]
  • [Cites] World J Gastroenterol. 2006 Jul 21;12(27):4296-303 [16865769.001]
  • [Cites] Lancet Oncol. 2006 Aug;7(8):628-9 [16900606.001]
  • [Cites] Environ Sci Technol. 2006 Dec 15;40(24):7834-40 [17256535.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Oct;10(10):1055-62 [11588131.001]
  • (PMID = 18686719.001).
  • [ISSN] 1077-3525
  • [Journal-full-title] International journal of occupational and environmental health
  • [ISO-abbreviation] Int J Occup Environ Health
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 CP010125-12
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nitrates; 0 / Nitrites; 0 / Water Pollutants, Chemical
  • [Other-IDs] NLM/ NIHMS162722; NLM/ PMC2797489
  •  go-up   go-down


78. Jang JS, Yim HJ, Lee BJ, Kim SY, Kim DI, Lee HS, Lee SW, Choi JH: [A case of hepatic metastasis of small cell carcinoma from mixed small cell carcinoma and adenocarcinoma of the stomach]. Korean J Gastroenterol; 2007 Sep;50(3):193-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of hepatic metastasis of small cell carcinoma from mixed small cell carcinoma and adenocarcinoma of the stomach].
  • Primary small cell carcinoma (SCC) of stomach is a rare and highly aggressive malignancy with extremely poor prognosis.
  • We report a 71-year-old man with upper abdominal pain diagnosed as single hepatic metastasis of SCC from mixed SCC and adenocarcinoma of the stomach.
  • An endoscopic examination showed the presence of Borrmann type 2 gastric cancer, 2 cm in size on the lesser curvature of antrum.
  • On the basis of these findings, we made a final diagnosis of mixed SCC and adenocarcinoma of the stomach.
  • Conclusively, we report a case of hepatic metastasis of SCC only from mixed SCC adenocarcinoma of the stomach.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / secondary. Liver Neoplasms / diagnosis. Liver Neoplasms / secondary. Stomach Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Stomach carcinoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17885286.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


79. Capellá G, Pera G, Sala N, Agudo A, Rico F, Del Giudicce G, Plebani M, Palli D, Boeing H, Bueno-de-Mesquita HB, Carneiro F, Berrino F, Vineis P, Tumino R, Panico S, Berglund G, Simán H, Nyrén O, Hallmans G, Martinez C, Dorronsoro M, Barricarte A, Navarro C, Quirós JR, Allen N, Key T, Bingham S, Caldas C, Linseisen J, Nagel G, Overvad K, Tjonneland A, Boshuizen HC, Peeters PH, Numans ME, Clavel-Chapelon F, Trichopoulou A, Lund E, Jenab M, Kaaks R, Riboli E, González CA: DNA repair polymorphisms and the risk of stomach adenocarcinoma and severe chronic gastritis in the EPIC-EURGAST study. Int J Epidemiol; 2008 Dec;37(6):1316-25
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA repair polymorphisms and the risk of stomach adenocarcinoma and severe chronic gastritis in the EPIC-EURGAST study.
  • BACKGROUND: The contribution of genetic variation in DNA repair genes to gastric cancer (GC) risk remains essentially unknown.
  • Method A nested case control study within the EPIC cohort was performed including 246 gastric adenocarcinomas and 1175 matched controls.
  • RESULTS: No association was observed for any of these polymorphisms with stomach cancer risk.
  • CONCLUSION: Our study supports a role of ERCC2 in non-cardial GC but not in cardial cancer.
  • This is the first prospective study suggesting that individual variation in DNA repair may be relevant for gastric carcinogenesis, a finding that will require further confirmation validation in larger independent studies.
  • [MeSH-major] Adenocarcinoma / genetics. DNA Repair / genetics. Gastritis, Atrophic / genetics. Polymorphism, Genetic. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18641418.001).
  • [ISSN] 1464-3685
  • [Journal-full-title] International journal of epidemiology
  • [ISO-abbreviation] Int J Epidemiol
  • [Language] eng
  • [Grant] United Kingdom / British Heart Foundation / / ; United Kingdom / Cancer Research UK / / ; United Kingdom / Medical Research Council / / ; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Bacterial; 0 / Biomarkers; 9001-10-9 / Pepsinogen A; EC 3.6.4.12 / Xeroderma Pigmentosum Group D Protein; EC 5.99.- / ERCC2 protein, human
  •  go-up   go-down


80. Hu G, Shen J, Cheng L, Xiang D, Zhang Z, He M, Lu H, Zhu S, Wu M, Yu Y, Wang X, Han W: Purification of a bioactive recombinant human Reg IV expressed in Escherichia coli. Protein Expr Purif; 2010 Feb;69(2):186-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Reg IV is highly expressed in the gastrointestinal tract and markedly up-regulated in colon adenocarcinoma, pancreatic cancer, gastric adenocarcinoma, and inflammatory bowel disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19699332.001).
  • [ISSN] 1096-0279
  • [Journal-full-title] Protein expression and purification
  • [ISO-abbreviation] Protein Expr. Purif.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Lectins, C-Type; 0 / REG4 protein, human; 0 / Recombinant Proteins
  •  go-up   go-down


81. Bakir T, Aliyazicioglu Y, Bektas A, Siviloglu C, Ozgur O: Hepatoid adenocarcinoma of the stomach: report of five cases and review of the literature. Acta Gastroenterol Belg; 2006 Jul-Sep;69(3):330-7
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatoid adenocarcinoma of the stomach: report of five cases and review of the literature.
  • We report on a rare hepatoid adenocarcinoma of the stomach producing alpha-fetoprotein (AFP) in five cases.
  • Our experience together with what has been reported in literature suggest that the course of hepatoid adenocarcinoma of the stomach is more aggressive than an ordinary adenocarcinoma and that from a diagnostic point of view distinction from an adenocarcinoma may be accomplished histochemically and by measuring serum AFP levels.
  • [MeSH-major] Adenocarcinoma / secondary. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17168134.001).
  • [ISSN] 1784-3227
  • [Journal-full-title] Acta gastro-enterologica Belgica
  • [ISO-abbreviation] Acta Gastroenterol. Belg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / alpha-Fetoproteins
  • [Number-of-references] 81
  •  go-up   go-down


82. Crusius JB, Canzian F, Capellá G, Peña AS, Pera G, Sala N, Agudo A, Rico F, Del Giudice G, Palli D, Plebani M, Boeing H, Bueno-de-Mesquita HB, Carneiro F, Pala V, Save VE, Vineis P, Tumino R, Panico S, Berglund G, Manjer J, Stenling R, Hallmans G, Martínez C, Dorronsoro M, Barricarte A, Navarro C, Quirós JR, Allen N, Key TJ, Binghan S, Caldas C, Linseisen J, Kaaks R, Overvad K, Tjønneland A, Büchner FC, Peeters PH, Numans ME, Clavel-Chapelon F, Trichopoulou A, Lund E, Jenab M, Rinaldi S, Ferrari P, Riboli E, González CA: Cytokine gene polymorphisms and the risk of adenocarcinoma of the stomach in the European prospective investigation into cancer and nutrition (EPIC-EURGAST). Ann Oncol; 2008 Nov;19(11):1894-902
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokine gene polymorphisms and the risk of adenocarcinoma of the stomach in the European prospective investigation into cancer and nutrition (EPIC-EURGAST).
  • BACKGROUND: The relative contribution to gastric cancer (GC) risk of variants in genes that determine the inflammatory response remains mostly unknown and results from genotyping studies are inconsistent.
  • PATIENTS AND METHODS: A nested case-control study within the prospective European Prospective Investigation into Cancer and Nutrition cohort was carried out, including 248 gastric adenocarcinomas and 770 matched controls.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18628242.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Grant] United Kingdom / British Heart Foundation / / ; United Kingdom / Cancer Research UK / / ; United Kingdom / Department of Health / / ; United Kingdom / Medical Research Council / / ; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interleukins; 0 / Lymphotoxin-alpha; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


83. Kunisaki C, Akiyama H, Nomura M, Matsuda G, Otsuka Y, Ono HA, Nagahori Y, Takahashi M, Kito F, Shimada H: Clinicopathological properties of poorly-differentiated adenocarcinoma of the stomach: comparison of solid- and non-solid-types. Anticancer Res; 2006 Jan-Feb;26(1B):639-46
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological properties of poorly-differentiated adenocarcinoma of the stomach: comparison of solid- and non-solid-types.
  • BACKGROUND: The purpose of this study was to clarify the clinicopathological and biological properties of the poorly-differentiated types of gastric carcinoma (solid-type and non-solid-type).
  • PATIENTS AND METHODS: A total of 1,558 patients with primary gastric adenocarcinomas were enrolled in this study.
  • CONCLUSION: Therapeutic strategies should be based on the histological type of the tumor in patients with poorly-differentiated gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16739333.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


84. Lindblad M, García Rodríguez LA, Chandanos E, Lagergren J: Hormone replacement therapy and risks of oesophageal and gastric adenocarcinomas. Br J Cancer; 2006 Jan 16;94(1):136-41
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hormone replacement therapy and risks of oesophageal and gastric adenocarcinomas.
  • Oesophageal and gastric adenocarcinoma share an unexplained male predominance, which would be explained by the hypothesis that oestrogens are protective in this respect.
  • We carried out a nested case-control study of hormone replacement therapy (HRT) among 299 women with oesophageal cancer, 313 with gastric cancer, and 3191 randomly selected control women, frequency matched by age and calendar year in the General Practitioners Research Database in the United Kingdom.
  • Among 1 619 563 person-years of follow-up, more than 50% reduced risk of gastric adenocarcinoma was found among users of HRT compared to nonusers (odds ratio (OR), 0.48, 95% confidence interval (CI) 0.29-0.79).
  • This inverse association appeared to be stronger for gastric noncardia (OR 0.34, 95% CI 0.14-0.78) and weaker for gastric cardia tumours (OR 0.68, 95% CI 0.23-2.01).
  • There was no association between HRT and oesophageal adenocarcinoma (OR 1.17, 95% CI 0.41-3.32).
  • [MeSH-major] Adenocarcinoma / etiology. Esophageal Neoplasms / etiology. Hormone Replacement Therapy. Stomach Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Hormone Replacement Therapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Causes Control. 2003 Feb;14(1):53-9 [12708725.001]
  • [Cites] J Chronic Dis. 1980;33(10):595-605 [7410520.001]
  • [Cites] N Engl J Med. 2003 Dec 4;349(23):2241-52 [14657432.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 3;96(5):388-96 [14996860.001]
  • [Cites] Semin Oncol. 2004 Aug;31(4):450-64 [15297938.001]
  • [Cites] J Natl Cancer Inst. 1980 Dec;65(6):1201-7 [7001123.001]
  • [Cites] Cancer Res. 1982 Dec;42(12):5181-2 [7139622.001]
  • [Cites] Int J Cancer. 1985 Nov 15;36(5):529-33 [4055127.001]
  • [Cites] BMJ. 1991 Mar 30;302(6779):766-8 [2021768.001]
  • [Cites] Gastroenterology. 1991 Jul;101(1):66-9 [2044927.001]
  • [Cites] Eur J Cancer Prev. 1992 Apr;1(3):259-64 [1467771.001]
  • [Cites] Gastroenterology. 1993 Oct;105(4):1098-103 [8405854.001]
  • [Cites] Gut. 1993 Dec;34(12):1672-6 [8282253.001]
  • [Cites] Int J Cancer. 1994 Mar 15;56(6):812-5 [8119771.001]
  • [Cites] Int J Cancer. 1994 Dec 15;59(6):761-4 [7989115.001]
  • [Cites] N Engl J Med. 1995 Jul 6;333(1):32-41 [7776992.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 3;89(17):1277-84 [9293918.001]
  • [Cites] IARC Sci Publ. 1997;(138):325-9 [9353673.001]
  • [Cites] Br J Clin Pharmacol. 1998 May;45(5):419-25 [9643612.001]
  • [Cites] Surg Today. 1998;28(10):1007-14 [9786571.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Oct;7(10):913-5 [9796637.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Ann Intern Med. 1999 Jun 1;130(11):883-90 [10375336.001]
  • [Cites] Endocrinology. 1999 Oct;140(10):4886-94 [10499548.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2203-7 [15598781.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):444-50 [15734971.001]
  • [Cites] Int J Cancer. 2000 Feb 1;85(3):340-6 [10652424.001]
  • [Cites] Obstet Gynecol. 1999 May;93(5 Pt 2):880-8 [10912438.001]
  • [Cites] Cancer Causes Control. 2000 Oct;11(9):869-74 [11075877.001]
  • [Cites] Br J Cancer. 2001 Aug 3;85(3):341-5 [11487262.001]
  • [Cites] N Engl J Med. 2001 Sep 13;345(11):784-9 [11556297.001]
  • [Cites] Int J Epidemiol. 2001 Dec;30(6):1415-25 [11821356.001]
  • [Cites] Int J Cancer. 2002 Feb 20;97(6):833-8 [11857364.001]
  • [Cites] Lancet Oncol. 2001 Sep;2(9):533-43 [11905707.001]
  • [Cites] J Cancer Res Clin Oncol. 2002 Jun;128(6):319-24 [12073050.001]
  • [Cites] Anticancer Res. 2002 May-Jun;22(3):1459-61 [12168823.001]
  • [Cites] JAMA. 2002 Aug 21;288(7):872-81 [12186605.001]
  • [Cites] Gastric Cancer. 2002;5(4):213-9 [12491079.001]
  • [Cites] J Clin Epidemiol. 2003 Jan;56(1):1-9 [12589864.001]
  • [Cites] Int J Cancer. 2003 Jun 20;105(3):408-12 [12704678.001]
  • [Cites] Pharmacotherapy. 2003 May;23(5):686-9 [12741446.001]
  • (PMID = 16404367.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2361087
  •  go-up   go-down


85. Yang CK, Zhao WJ, Dai QB, Zhang HH, Zheng W: [Clinical characteristics, diagnosis and treatment of hepatoid adenocarcinoma of the stomach]. Zhonghua Wei Chang Wai Ke Za Zhi; 2007 May;10(3):245-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical characteristics, diagnosis and treatment of hepatoid adenocarcinoma of the stomach].
  • OBJECTIVE: To investigate the clinical characteristics,diagnosis and treatment of hepatoid adenocarcinoma of the stomach.
  • METHODS: Clinical data of 13 hepatoid adenocarcinomas of the stomach, collected from 201 cases of gastric cancer, were analyzed retrospectively.
  • RESULTS: Of the 201 gastric carcinomas, there were 13 AFP-producing adenocarcinomas of the stomach, the positive rate was 6.5%.
  • Of the 13 hepatoid adenocarcinomas of the stomach, 10 cases were in gastric antrum and 10 cases were poorly differentiated.
  • The metastasis rates of liver and lymph node in hepatoid adenocarcinoma of stomach were higher than those in non-hepatoid adenocarcinoma of stomach.
  • The treatment of hepatoid adenocarcinoma of stomach depended mainly on radical resection, and adjuvant chemotherapy was needed.The prognosis of hepatoid adenocarcinoma of stomach was poor.
  • CONCLUSION: Hepatoid adenocarcinoma of the stomach has its own special tumor biological behavior and poor prognosis.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / therapy. Stomach Neoplasms / diagnosis. Stomach Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17520383.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


86. Liu X, Cheng Y, Sheng W, Lu H, Xu X, Xu Y, Long Z, Zhu H, Wang Y: Analysis of clinicopathologic features and prognostic factors in hepatoid adenocarcinoma of the stomach. Am J Surg Pathol; 2010 Oct;34(10):1465-71
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of clinicopathologic features and prognostic factors in hepatoid adenocarcinoma of the stomach.
  • OBJECTIVE: To investigate the different nature between hepatoid adenocarcinoma of the stomach (HAS) and common stomach cancer without the hepatoid differentiation areas (non-HAS).
  • METHODS: From January 1996 to December 2007, 45 patients were diagnosed as HAS on the basis of the characteristic histologic features resembling hepatocellular carcinoma in Fudan University Shanghai Cancer Center.
  • In addition, 225 stage-matched common stomach cancer patients were selected as controls.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Hepatocellular / pathology. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20871221.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


87. M A M, Pera G, Agudo A, Bueno-de-Mesquita HB, Palli D, Boeing H, Carneiro F, Berrino F, Sacerdote C, Tumino R, Panico S, Berglund G, Manjer J, Johansson I, Stenling R, Martinez C, Dorronsoro M, Barricarte A, Tormo MJ, Quiros JR, Allen N, Key TJ, Bingham S, Linseisen J, Kaaks R, Overvad K, Jensen M, Olsen A, Tjønneland A, Peeters PH, Numans ME, Ocké MC, Clavel-Chapelon F, Boutron-Ruault MC, Trichopoulou A, Lund E, Slimani N, Jenab M, Ferrari P, Riboli E, González CA: Cereal fiber intake may reduce risk of gastric adenocarcinomas: the EPIC-EURGAST study. Int J Cancer; 2007 Oct 01;121(7):1618-23
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cereal fiber intake may reduce risk of gastric adenocarcinomas: the EPIC-EURGAST study.
  • Numerous case-control studies suggest dietary fiber may reduce risk of gastric cancer, but this has not been confirmed prospectively.
  • A previous case-control study reported reduced risk of gastric cardia adenocarcinomas associated with cereal fiber, but not with fruit or vegetable fiber.
  • This study prospectively examines associations between fiber from different food sources and incident gastric adenocarcinomas (GC) among more than 435,000 subjects from 10 countries participating in the European Prospective Investigation into Cancer and Nutrition study.
  • [MeSH-major] Adenocarcinoma / prevention & control. Dietary Fiber / administration & dosage. Edible Grain. Stomach Neoplasms / prevention & control

  • MedlinePlus Health Information. consumer health - Dietary Fiber.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17582605.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U105630924
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


88. Ronellenfitsch U, Ströbel P, Schwarzbach MH, Staiger WI, Gragert D, Kähler G: A composite adenoendocrine carcinoma of the stomach arising from a neuroendocrine tumor. J Gastrointest Surg; 2007 Nov;11(11):1573-5
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A composite adenoendocrine carcinoma of the stomach arising from a neuroendocrine tumor.
  • Gastric neuroendocrine tumors (carcinoids) are relatively uncommon neoplasms.
  • This disorder, however, is also a risk factor for the development of conventional gastric adenocarcinomas.
  • We report a case of a patient with autoimmune body gastritis and a well-differentiated neuroendocrine tumor of the stomach, which was removed with endoscopic full-thickness resection in sano upon signs of invasive growth several years after its first diagnosis.
  • Histological examination surprisingly showed a composite glandular-endocrine gastric carcinoma.
  • We discuss the histopathological genesis of the tumor and provide evidence that endoscopic full-thickness resection might be an oncologically appropriate minimally invasive treatment for such gastric lesions.
  • [MeSH-major] Adenocarcinoma / pathology. Neuroendocrine Tumors / pathology. Stomach Neoplasms / pathology

  • Genetic Alliance. consumer health - Pancreatic islet cell tumors.
  • Genetic Alliance. consumer health - Stomach carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17436049.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromogranin A
  •  go-up   go-down


89. Dragovich T, McCoy S, Fenoglio-Preiser CM, Wang J, Benedetti JK, Baker AF, Hackett CB, Urba SG, Zaner KS, Blanke CD, Abbruzzese JL: Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J Clin Oncol; 2006 Oct 20;24(30):4922-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.
  • PURPOSE: A phase II trial of the oral epidermal growth factor receptor (EGFR) inhibitor erlotinib in patients with gastroesophageal adenocarcinomas stratified according to primary tumor location into two groups: gastroesophageal junction (GEJ)/cardia and distal gastric adenocarcinomas.
  • PATIENTS AND METHODS: Patients with a histologically proven diagnosis of adenocarcinoma of the GEJ or stomach (ST) that was unresectable or metastatic; presence of measurable disease; no prior chemotherapy for advanced or metastatic cancer; Zubrod performance status (PS) of 0 to 1; and adequate renal, hepatic, and hematologic function were treated with erlotinib 150 mg/d orally.
  • CONCLUSION: Erlotinib is active in patients with GEJ adenocarcinomas, but appears inactive in gastric cancers.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Esophageal Neoplasms / drug therapy. Esophagogastric Junction. Protein Kinase Inhibitors / therapeutic use. Quinazolines / therapeutic use. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2007 Mar 1;25(7):910; author reply 911 [17327617.001]
  • [ErratumIn] J Clin Oncol. 2007 Jun 1;25(16):2334
  • (PMID = 17050876.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA04919; United States / NCI NIH HHS / CA / CA11083; United States / NCI NIH HHS / CA / CA12644; United States / NCI NIH HHS / CA / CA13612; United States / NCI NIH HHS / CA / CA14028; United States / NCI NIH HHS / CA / CA16385; United States / NCI NIH HHS / CA / CA22433; United States / NCI NIH HHS / CA / CA27057; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA35090; United States / NCI NIH HHS / CA / CA35128; United States / NCI NIH HHS / CA / CA35176; United States / NCI NIH HHS / CA / CA35178; United States / NCI NIH HHS / CA / CA35192; United States / NCI NIH HHS / CA / CA35431; United States / NCI NIH HHS / CA / CA38926; United States / NCI NIH HHS / CA / CA42777; United States / NCI NIH HHS / CA / CA45450; United States / NCI NIH HHS / CA / CA45560; United States / NCI NIH HHS / CA / CA45807; United States / NCI NIH HHS / CA / CA45808; United States / NCI NIH HHS / CA / CA46441; United States / NCI NIH HHS / CA / CA58658; United States / NCI NIH HHS / CA / CA58686; United States / NCI NIH HHS / CA / CA58723; United States / NCI NIH HHS / CA / CA58882; United States / NCI NIH HHS / CA / CA63848; United States / NCI NIH HHS / CA / CA63850; United States / NCI NIH HHS / CA / CA67575; United States / NCI NIH HHS / CA / CA67663; United States / NCI NIH HHS / CA / CA76447; United States / NCI NIH HHS / CA / CA76448; United States / NCI NIH HHS / CA / CA86780
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride
  •  go-up   go-down


90. Takasu S, Tsukamoto T, Ushijima T, Yamashita S, Ogasawara N, Ban H, Yanai T, Masegi T, Tatematsu M: Cyclin D1 overexpression in N-methyl-N'-nitro-N-nitrosoguanidine-induced rat gastric adenocarcinomas. Exp Toxicol Pathol; 2007 Nov;59(3-4):171-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cyclin D1 overexpression in N-methyl-N'-nitro-N-nitrosoguanidine-induced rat gastric adenocarcinomas.
  • Changes in cell cycle regulation are involved in many human cancers, including gastric cancer.
  • In the present study, cyclin D1 expression and localization were immunohistochemically analyzed in 23 N-methyl-N'-nitro-N-nitrosoguanidine-induced rat gastric adenocarcinomas and compared with findings for beta-catenin.
  • Cyclin D1 was also found to be accumulated in gastric glands within normal-looking mucosa, these perhaps representing preneoplastic lesions for cancers with membranous beta-catenin accumulation.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinogens / toxicity. Cyclins / metabolism. Methylnitronitrosoguanidine / toxicity. Stomach Neoplasms / metabolism
  • [MeSH-minor] Animals. Cell Membrane / drug effects. Cell Membrane / metabolism. Cell Membrane / pathology. Cell Nucleus / drug effects. Cell Nucleus / metabolism. Cell Nucleus / pathology. Cyclin D. Cytoplasm / drug effects. Cytoplasm / metabolism. Cytoplasm / pathology. Gastric Mucosa / drug effects. Gastric Mucosa / metabolism. Gastric Mucosa / pathology. Immunohistochemistry. Male. Rats. Rats, Inbred ACI. beta Catenin / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. N-METHYL-N'-NITRO-N-NITROSOGUANIDINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17855062.001).
  • [ISSN] 0940-2993
  • [Journal-full-title] Experimental and toxicologic pathology : official journal of the Gesellschaft für Toxikologische Pathologie
  • [ISO-abbreviation] Exp. Toxicol. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Ctnnb1 protein, rat; 0 / Cyclin D; 0 / Cyclins; 0 / beta Catenin; 12H3O2UGSF / Methylnitronitrosoguanidine
  •  go-up   go-down


91. Burbano RR, Assumpção PP, Leal MF, Calcagno DQ, Guimarães AC, Khayat AS, Takeno SS, Chen ES, De Arruda Cardoso Smith M: C-MYC locus amplification as metastasis predictor in intestinal-type gastric adenocarcinomas: CGH study in Brazil. Anticancer Res; 2006 Jul-Aug;26(4B):2909-14
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] C-MYC locus amplification as metastasis predictor in intestinal-type gastric adenocarcinomas: CGH study in Brazil.
  • BACKGROUND: The genetic events involved in gastric cancer, the third most frequent cancer in the world with a high incidence in Pard State, Brazil, remain largely unknown.
  • MATERIALS AND METHODS: Twenty-one primary gastric adenocarcinomas were investigated by comparative genomic hybridization (CGH) and the relationships between genomic abnormalities and histopathological features were evaluated.
  • CONCLUSION: C-MYC locus amplification may be predictor of aggressiveness in intestinal-type gastric cancer, playing an important role in its development and progression.
  • Gastric adenocarcinomas of differing histopathological features were associated with distinct genetic alterations, supporting the hypothesis that they evolve through distinct genetic pathways.
  • [MeSH-major] Adenocarcinoma / genetics. Chromosome Aberrations. Genes, myc. Stomach Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16886612.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


92. Hirano Y, Hara T, Nozawa H, Oyama K, Ohta N, Omura K, Watanabe G, Niwa H: Combined choriocarcinoma, neuroendocrine cell carcinoma and tubular adenocarcinoma in the stomach. World J Gastroenterol; 2008 May 28;14(20):3269-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined choriocarcinoma, neuroendocrine cell carcinoma and tubular adenocarcinoma in the stomach.
  • We described a patient with adenocarcinoma of the stomach combined with choriocarcinoma and neuroendocrine cell carcinoma.
  • Gastric fiberscopy revealed a large tumor occupying the cardial region and anterior wall of the gastric body.
  • Choriocarcinoma, small cell carcinoma and tubular adenocarcinoma existed in the gastric tumor.
  • The prognosis for gastric adenocarcinoma with choriocarcinoma and neuroendocrine cell carcinoma is exceedingly poor.
  • This is the first reported case of gastric cancer with these three pathological features.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Neuroendocrine / pathology. Choriocarcinoma / pathology. Liver Neoplasms / secondary. Stomach Neoplasms / pathology


93. Hoyo C, Schildkraut JM, Murphy SK, Chow WH, Vaughan TL, Risch H, Marks JR, Jirtle RL, Calingaert B, Mayne S, Fraumeni J Jr, Gammon MD: IGF2R polymorphisms and risk of esophageal and gastric adenocarcinomas. Int J Cancer; 2009 Dec 1;125(11):2673-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IGF2R polymorphisms and risk of esophageal and gastric adenocarcinomas.
  • We tested the hypothesis that the common nonsynonymous genetic variants in M6P/IGF2R c.901C > G (Leu > Val) in exon 6 and c.5002G > A (Gly > Arg) in exon 34 are associated with risk of esophageal and gastric cancers.
  • Study participants in this population-based study comprise 197 controls and 182 cases, including 105 with esophageal-gastric cardia adenocarcinoma (EGA), 57 with noncardia gastric adenocarcinoma and 20 with esophageal squamous (ES) cell carcinoma.
  • Among white males, odds ratios (ORs) were elevated in relation to carrying at least 1 c.901C > G allele for EGA [OR = 1.9; 95% confidence intervals (CIs) = 1.0-3.6] and noncardia gastric cancer (OR = 2.5; 95% CI = 1.2-5.5), but not ES.
  • These findings suggest that nonsynonymous polymorphisms in M6P/IGF2R may contribute to the risks of EGA and noncardia adenocarcinomas.

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827857229 for PMID:19626700 [PharmGKB] .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2000 Mar 16;19(12):1572-8 [10734317.001]
  • [Cites] J Mol Endocrinol. 2009 Apr;42(4):341-56 [19208780.001]
  • [Cites] Mol Cell. 2000 Apr;5(4):707-16 [10882106.001]
  • [Cites] Hum Mutat. 2001;18(1):25-31 [11438990.001]
  • [Cites] JAMA. 2003 Jan 1;289(1):76-9 [12503980.001]
  • [Cites] Endocrinology. 2003 Mar;144(3):955-66 [12586773.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Jan 15;88(2):580-4 [1846448.001]
  • [Cites] Stem Cells. 1997;15(3):190-7 [9170210.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 3;89(17):1277-84 [9293918.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 21;90(2):150-5 [9450576.001]
  • [Cites] Breast Cancer Res Treat. 1998 Feb;47(3):269-81 [9516081.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 19;97(2):142-6 [15657344.001]
  • [Cites] Gastroenterology. 2005 Mar;128(3):607-9 [15765396.001]
  • [Cites] BMC Genet. 2005;6:22 [15885138.001]
  • [Cites] Eur J Cancer. 2006 May;42(8):1151-8 [16630714.001]
  • [Cites] Cancer Causes Control. 2006 Sep;17(7):971-81 [16841264.001]
  • [Cites] Acta Paediatr. 2007 Mar;96(3):363-7 [17407457.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Aug;16(8):1667-74 [17684144.001]
  • [Cites] Cancer Causes Control. 2007 Nov;18(9):1039-46 [17665311.001]
  • [Cites] Structure. 2007 Sep;15(9):1065-78 [17850746.001]
  • [ErratumIn] Int J Cancer. 2010 Feb 1;126(3):799. Calingeart, Brian [corrected to Calingaert, Brian]
  • (PMID = 19626700.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K05 CA124911; United States / NCI NIH HHS / CA / CA104517-02; United States / NCI NIH HHS / CA / CA104517-03; United States / NCI NIH HHS / CA / K01 CA104517-02; United States / NCI NIH HHS / CA / K01 CA104517; United States / NCI NIH HHS / CA / K01 CA104517-05; United States / NCI NIH HHS / CA / K01 CA104517-03
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptor, IGF Type 2
  • [Other-IDs] NLM/ NIHMS137939; NLM/ PMC3008656
  •  go-up   go-down


94. Kamangar F, Dawsey SM, Blaser MJ, Perez-Perez GI, Pietinen P, Newschaffer CJ, Abnet CC, Albanes D, Virtamo J, Taylor PR: Opposing risks of gastric cardia and noncardia gastric adenocarcinomas associated with Helicobacter pylori seropositivity. J Natl Cancer Inst; 2006 Oct 18;98(20):1445-52
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Opposing risks of gastric cardia and noncardia gastric adenocarcinomas associated with Helicobacter pylori seropositivity.
  • BACKGROUND: Colonization with Helicobacter pylori is a risk factor for gastric adenocarcinoma, but the magnitude of this association and its relationship to anatomic location of the cancer, duration of follow-up, age at diagnosis, histologic subtype, and H. pylori strain differences are less clear.
  • METHODS: Case and control subjects were selected from the 29,133 50- to 69-year-old males recruited into the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study.
  • From 1985 to 1999, 243 incident cases of gastric adenocarcinoma were diagnosed in cohort members.
  • Serum samples from 234 case subjects (173 with noncardia gastric cancers and 61 with gastric cardia cancers) and 234 age-matched control subjects were assayed for antibodies against H. pylori whole-cell and CagA antigens.
  • We fit conditional logistic regression models to estimate the unadjusted and adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for the association of H. pylori seropositivity, defined as seropositivity to either whole-cell or CagA antigens, with noncardia gastric and gastric cardia cancers.
  • RESULTS: H. pylori seropositivity was strongly associated with the risk of noncardia gastric cancer (adjusted OR = 7.9, 95% CI = 3.0 to 20.9) but was inversely associated with the risk of gastric cardia cancer (adjusted OR = 0.31, 95% CI = 0.11 to 0.89). H. pylori seropositivity rates did not vary statistically significantly by length of follow-up, age at diagnosis, or histologic subtype.
  • A calculation of rates showed that the absolute risks of noncardia gastric and cardia gastric adenocarcinomas in the H. pylori-positive participants of this cohort would be 63 and 12 per 100,000 person-years, respectively, whereas corresponding rates in H. pylori-negative participants would be 8 and 37 per 100,000 person-years, respectively.
  • CONCLUSION: H. pylori is a strong risk factor for noncardia gastric cancer but is inversely associated with the risk of gastric cardia cancer.
  • These findings bolster the hypothesis that decreasing H. pylori prevalence during the past century may have contributed to lower rates of noncardia cancer and higher rates of cardia cancer in Western countries.
  • [MeSH-major] Adenocarcinoma / epidemiology. Adenocarcinoma / microbiology. Cardia. Helicobacter Infections / complications. Helicobacter Infections / epidemiology. Helicobacter pylori. Stomach Neoplasms / epidemiology. Stomach Neoplasms / microbiology


95. Saint-Gerons Marzo S, Catón Santarén B, Anda Fernandez JM: [Metastasis in the palatine tonsil as the first sign of a gastric adenocarcinoma]. Acta Otorrinolaringol Esp; 2005 Nov;56(9):439-40
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metastasis in the palatine tonsil as the first sign of a gastric adenocarcinoma].
  • [Transliterated title] Metastasis en la amígdala palatina como primera manifestación de un adenocarcinoma gástrico.
  • Gastric adenocarcinomas rarely give rise to metastases in the palatine tonsils; twelve such cases have been published.
  • We present a patient with a tumour of the palatine tonsil and cervical lymph node involvement who was diagnosed as having an adenocarcinoma of "signet ring" cells in the histopathology and cytology studies.
  • Finding such cells directed us to the stomach in our search for the primary.
  • [MeSH-major] Carcinoma, Signet Ring Cell / secondary. Oropharyngeal Neoplasms / secondary. Palatine Tonsil. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16353792.001).
  • [ISSN] 0001-6519
  • [Journal-full-title] Acta otorrinolaringológica española
  • [ISO-abbreviation] Acta Otorrinolaringol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 7
  •  go-up   go-down


96. Kaźmierczak M, Lewandowski K, Wojtukiewicz MZ, Turowiecka Z, Kołacz E, Lojko A, Skrzydlewska E, Zawilska K, Komarnicki M: Cancer procoagulant in patients with adenocarcinomas. Blood Coagul Fibrinolysis; 2005 Nov;16(8):543-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer procoagulant in patients with adenocarcinomas.
  • Cancer procoagulant (CP) is a cysteine proteinase that may be produced by malignant and foetal tissue.
  • The possible role of CP in the pathogenesis of cancer-related thrombosis has been suggested recently.
  • The purpose of the study was to evaluate coagulation prothrombotic markers and their relation to CP concentration in the blood of patients with gastrointestinal adenocarcinomas (GIAC).
  • The study group consisted of 45 patients with confirmed diagnosis of adenocarcinoma (stomach, 18 patients; colon, 27 patients) and without evident metastatic disease.
  • [MeSH-major] Adenocarcinoma / blood. Colonic Neoplasms / blood. Cysteine Endopeptidases / blood. Neoplasm Proteins / blood. Stomach Neoplasms / blood. Venous Thrombosis / blood

  • MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16269926.001).
  • [ISSN] 0957-5235
  • [Journal-full-title] Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
  • [ISO-abbreviation] Blood Coagul. Fibrinolysis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Blood Proteins; 0 / Neoplasm Proteins; EC 3.4.22.- / Cysteine Endopeptidases; EC 3.4.22.26 / cancer procoagulant
  •  go-up   go-down


97. Caruso RA, Basile G, Crisafulli C, Pizzi G, Finocchiaro G, Fedele F, Paparo D, Parisi A: Granulomatous inflammatory reaction in human gastric adenocarcinomas: a light and electron microscopy study. Ultrastruct Pathol; 2009 Dec;33(6):269-73
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulomatous inflammatory reaction in human gastric adenocarcinomas: a light and electron microscopy study.
  • The authors report 9 cases of papillary-tubular gastric adenocarcinomas characterized by mature granulomas associated with recent microhemorrhages.
  • This study provides morphological examples of skewed type II macrophage infiltration in gastric adenocarcinomas that is involved in scavenging activity, particularly erythrophagocytosis, formation of mature (nonepithelioid granulomas), and heterotypic aggregation with eosinophils.
  • [MeSH-major] Adenocarcinoma / pathology. Granuloma / pathology. Macrophages / immunology. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19929174.001).
  • [ISSN] 1521-0758
  • [Journal-full-title] Ultrastructural pathology
  • [ISO-abbreviation] Ultrastruct Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Antigens, Neoplasm; 0 / CD68 antigen, human
  •  go-up   go-down


98. Siriwardana HD, Pathirana A: Adenocarcinoma of the stomach in a tertiary care hospital in Sri Lanka. Ceylon Med J; 2007 Jun;52(2):53-5
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the stomach in a tertiary care hospital in Sri Lanka.
  • OBJECTIVES: Adenocarcinoma of the stomach carries a dismal prognosis when it presents late.
  • Our objective was to describe the location of the tumour, stage at presentation, resectability and survival in a cohort of patients with adenocarcinoma of the stomach, presenting to a tertiary referral centre.
  • DESIGN AND SETTING: Data were collected retrospectively from all patients with gastric neoplasms who presented to the University Surgical Unit, Colombo South Teaching Hospital from May 2000 to October 2006.
  • RESULTS: Ninety three patients presented with malignant gastric neoplasms during this period.
  • Majority (86/93) were adenocarcinomas.
  • 52.6% of tumours were in the proximal stomach involving the cardia.
  • Thirty per cent involved the body, and 17.5% the distal stomach.
  • There were no patients in our series with early gastric cancer.
  • CONCLUSION: All our patients presented with advanced gastric cancer and the majority had unresectable disease.
  • The high proportion of patients having proximal gastric carcinoma is similar to the recent changes seen in the west.
  • [MeSH-major] Adenocarcinoma / surgery. Stomach Neoplasms / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17691560.001).
  • [ISSN] 0009-0875
  • [Journal-full-title] The Ceylon medical journal
  • [ISO-abbreviation] Ceylon Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Sri Lanka
  •  go-up   go-down


99. Kumashiro Y, Yao T, Aishima S, Hirahashi M, Nishiyama K, Yamada T, Takayanagi R, Tsuneyoshi M: Hepatoid adenocarcinoma of the stomach: histogenesis and progression in association with intestinal phenotype. Hum Pathol; 2007 Jun;38(6):857-63
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatoid adenocarcinoma of the stomach: histogenesis and progression in association with intestinal phenotype.
  • Hepatoid adenocarcinoma is an extrahepatic tumor characterized by morphological similarities to hepatocellular carcinoma.
  • The lesions contain a tubular adenocarcinoma that seems to develop "hepatoid" features, but the relation between the tubular adenocarcinomatous and the hepatoid components remains unclear.
  • We compared the cellular phenotypes of 23 cases of hepatoid adenocarcinoma of the stomach having tubular adenocarcinomatous components with 69 cases of non-hepatoid adenocarcinoma of the stomach.
  • Afterward, we examined the expression of CDX2 and p53 in the tubular adenocarcinomatous and hepatoid components of hepatoid adenocarcinoma.
  • Both components of hepatoid adenocarcinoma were classified into 4 phenotypic categories according to the immunohistochemical results for CD10, MUC2, MUC5AC, and MUC6.
  • In contrast, no gastric phenotype (MUC5AC+, MUC6+, MUC2-, CD10-) was observed in any of the hepatoid adenocarcinoma components.
  • These findings suggest that hepatoid adenocarcinoma arises from an adenocarcinoma with an intestinal phenotype and that its hepatoid component is in some way related to reduced CDX2 expression.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Homeodomain Proteins / biosynthesis. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology. Tumor Suppressor Protein p53 / biosynthesis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17320150.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Albumins; 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / MUC2 protein, human; 0 / MUC6 protein, human; 0 / Mucin-2; 0 / Mucin-6; 0 / Mucins; 0 / RNA, Messenger; 0 / Tumor Suppressor Protein p53; 0 / alpha-Fetoproteins; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


100. Rendón-Huerta E, Teresa F, Teresa GM, Xochitl GS, Georgina AF, Veronica ZZ, Montaño LF: Distribution and expression pattern of claudins 6, 7, and 9 in diffuse- and intestinal-type gastric adenocarcinomas. J Gastrointest Cancer; 2010 Mar;41(1):52-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution and expression pattern of claudins 6, 7, and 9 in diffuse- and intestinal-type gastric adenocarcinomas.
  • INTRODUCTION: Intestinal- and diffuse-type gastric adenocarcinomas differ in clinical outcome and genetic profile.
  • METHODS: Fifty paraffin-embedded tissue blocks of diffuse- and intestinal-type gastric adenocarcinomas and fresh gastric biopsies obtained endoscopically from 20 patients with a presumptive diagnosis of gastric cancer were analyzed.
  • CONCLUSION: Claudins 6, 7, and 9 expressions are closely related to gastric carcinogenesis, and their detection is a useful prognostic marker in "intestinal-" and "diffuse-type" gastric adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / metabolism. Membrane Proteins / biosynthesis. Stomach Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19960275.001).
  • [ISSN] 1941-6636
  • [Journal-full-title] Journal of gastrointestinal cancer
  • [ISO-abbreviation] J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CLDN7 protein, human; 0 / CLDN9 protein, human; 0 / Claudins; 0 / Membrane Proteins; 0 / claudin 6
  •  go-up   go-down






Advertisement